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SUMMARY	
Cellular	metabolic	pathway	usage	and	immune	cell	function	are	intimately	interlinked.	Whether	screening	metabolic	activity	of	defined	immune	cell	subsets	has	clinical	value,	or	 is	effective	in	guiding	discovery	of	molecular	immune	pathology,	has	not	been	previously	explored.		Here	 we	 prospectively	 screened	 glycolysis	 (extracellular	 acidification	 rates	 –	 ECAR)	 and	mitochondrial	 respiration	 (oxygen	 consumption	 rates	 –	 OCR)	 in	 B	 cells	 of	 healthy	 subjects	(n=15)	and	patients	with	primary	antibody	deficiency	 (PAD,	n	=	14).	Mean	ECAR	values	were	similar	 in	 both	 cohorts,	whereas	 –	 counterintuitively	 –	mean	OCR	 values	were	higher	 in	 PAD	patients.	 The	 highest	 OCR	 values	 grouped	 three	 study	 participants	with	 primary	 polyclonal	 B	cell	lymphocytosis	(PPBL),	a	condition	characterized	by	expansion	of	marginal	zone	(MZ)-like	B	cells.	Guided	by	this	B	cell	hyper-respiration	phenotype,	whole	exome	sequencing	identified	rare	germline	mutations	 in	 subunit	 A	 of	 the	 succinate	 dehydrogenase	 (SDHA)	 gene	 in	 these	 three	patients.	 Functional	 assays	 pinpointed	 SDHA	 gain-of-function	 driving	 fumarate	 accumulation,	which	 increased	 succination	 of	 several	 proteins	 –	 including	 KEAP1.	 Succination	 of	 KEAP1	promotes	accumulation	of	the	transcription	factor	Nrf-2,	and	inhibition	of	Nrf-2	established	that	the	inflammatory	output	of	MZ-like	B	cells	from	PPBL	patients	was	Nrf-2	dependent.	Our	study	identifies	pathologic	retrograde	signaling	as	a	novel	mechanism	underlying	 immune	dysregulation	in	PAD.	Specifically,	in	MZ-like	B	cells	of	the	PPBL	patients	enrolled	in	this	study,	SDHA-driven	accumulation	of	fumarate	engaged	retrograde	signaling	via	KEAP1–Nrf-2	to	drive	transcription	 of	 inflammatory	 cytokines.	 OCR	 screening	 of	 a	 clinically	 justified	 cell	 population	thus	helped	to	uncover	a	novel	molecular	disease	mechanisms	and	pinpointed	new	therapeutic	targets.		
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INTRODUCTION	
Primary	immunodeficiency	disorders	(PIDs)	are	rare	genetic	syndromes	that	arise	from	defects	in	 the	 immune	 system.	 More	 than	 350	 PID	 entities	 have	 been	 defined	 to	 date	 1.	 The	 most	common	symptomatic	adult	PID	is	primary	antibody	deficiency	(PAD)	–	ranging	from	complete	absence	 of	 antibodies	 to	 immunoglobulin	 subclass	 deficiency	 2,3.	 PADs	 are	 often	 due	 to	 B	 cell	intrinsic	defects,	 yet	 causes	and	genetics	of	PADs	are	 complex	and	only	 in	 a	minority	of	 cases	pathogenic	 mutations	 have	 been	 identified	 (e.g.	 mutations	 in	 the	 genes	 encoding	 for	 Bruton	tyrosine	kinase,	B	cell	activating	factor,	or	CD19)	3-10.		PADs	 can	present	with	 a	 spectrum	of	 clinical	 problems,	 ranging	 from	 infections	 only	 (approx.	50%	of	PAD	patients),	to	autoinflammation,	autoimmunity,	lymphoproliferation	and	allergy.		Infectious	 complications	 are	 predominantly	 characterized	 by	 prolonged,	 recurrent	 bacterial	infections	of	the	respiratory-	and	also	gastrointestinal	tract	2,11.	Persistent	infections	support	the	pathogenesis	 of	 inflammation	 and	 autoimmunity.	 Mechanistically,	 during	 an	 acute	 infection	immune	 cells	 rapidly	 proliferate	 in	 order	 to	 clear	 the	 pathogen	 and	 subsequently	 undergo	apoptosis	 to	 return	 to	 steady	 state.	High	burden	of	 apoptotic	 cell	 debris	 triggers	 formation	of	autoantibodies	and	accumulation	of	immune	complexes,	both	driver	of	autoinflammation	12-14.	A	broad	spectrum	of	autoimmune	disorders	 is	present	 in	PADs	varying	from	rheumatic	arthritis,	vasculitis,	 autoimmune	 haemolytic	 anaemia,	 immune	 thrombocytopenia,	 glomerulonephritis,	inflammatory	bowel	disease	and	also	dermatologic	disorders	as	vitiligo	or	psoriasis	14,15.	Lymphoproliferation	 as	 lymphadenopathy,	 splenomegaly	 and	 also	 lymphomas	 is	 another	frequent	 complication	 in	 PADs	 16,17. In	 addition	 of	 defective	 DNA	 repair	mechanism	 and	 viral	infections	as	EBV	and	HHV8,	also	chronic	inflammatory	processes	contribute	to	the	development	of	 lymphomas	 18,19. In	 particular	 the	 inflammatory	 cytokine	 IL-6,	 the	 major	 stimulus	 of	 the	synthesis	of	the	acute	phase	protein	CRP,	promotes	B	cell	proliferation	and	differentiation	and	is	a	growth	factor	for	malignant	B	cells	20-22.	In	deed	it	has	been	reported	that	IL-6	supports	virus	related	 lymphoproliferation	 and	 patients	with	 lymphomas	 and	 high	 IL-6	 serum	 concentration	have	been	associated	with	poorer	survival	rates	23.		 
 Susceptibility	 to	 infection	 is	 prevented	 by	 substitution	 of	 immunoglobulins.	 By	 contrast,	 non-infectious	 complications	 are	 not	 affected	 by	 immunoglobulin	 replacement	 therapy,	 and	contribute	to	excess	mortality	in	these	patients	24.			
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Over	the	last	years	our	understanding	of	how	cellular	metabolism	governs	immune	cell	function	has	 rapidly	 increased	 25-28.	 Specifically,	 various	 facets	of	 glycolysis	have	been	demonstrated	 to	impact	the	function	of	many	immune	cell	 types,	 including	B	cells	29-31.	Glutamine	metabolism	–	critically	required	for	effector	T	cell-,	NK	cell-,	macrophage-	and	DC	function	–	is	also	increased	in	 activated	 B	 cells	 31-34.	 Glutaminolysis	 can	 importantly	 contribute	 to	 ATP	 production,	 and	glutamine-derived	 α-ketoglutarate	 (α-KG)	 serves	 as	 anaplerotic	 source	 of	 tricarboxylic	 acid	(TCA)	metabolites	 32,33,35.	The	TCA	cycle	operates	 tightly	 integrated	with	 the	 respiratory	 chain	within	mitochondria	36,37.	The	respiratory	chain	complex	II,	known	as	succinate	dehydrogenase	(SDH),	 forms	 the	physical	 link	 between	 the	TCA	 and	 the	mitochondria	 respiratory	 chain.	 SDH	contains	 four	 subunits	 SDHA,	 SDHB,	 SDHC	 and	 SDHD.	 	 SDHA,	 the	 major	 catalytic	 domain,	oxidizes	 the	 TCA	 substrate	 succinate	 to	 fumarate	 and	 transfers	 generated	 electrons	 to	 its	subunits	38,39.		To	 facilitate	 more	 efficient	 transfer	 of	 electrons,	 the	 mitochondria	 respiratory	 complexes	 are	organized	in	larger	supramolecular	structures.	The	formation	of	supercomplexes	allows	higher	stability	and	consequently	leads	to	increased	activity	40.	Fueled	by	glycolysis,	glutaminolysis	or	β-oxidation	(i.e.	lipid	oxidation),	mitochondrial	oxidative	phosphorylation	 (OxPhos)	 is	 producing	 most	 of	 the	 ATP	 required	 for	 anabolic	 processes,	including	cell	proliferation	or	production	of	effector	molecules	secreted	by	immune	cells	41-43.			Importantly,	 several	 non-bioenergetic	 features	 of	 mitochondria	 further	 critically	 regulate	immune	 cell	 function.	 For	 example,	 in	 LPS-stimulated	 macrophages	 accumulation	 of	 the	 TCA	intermediate,	succinate,	promotes	transcription	of	inflammatory	genes	by	driving	mitochondrial	hyperpolarization	 and	 mitochondrial	 reactive	 oxygen	 species	 (mROS)	 dependent	 HIF-1α	stabilization	 44.	 In	CD4+	T	cells,	production	of	mROS	has	been	 linked	 to	 the	activation	of	NFAT	and	 production	 of	 IL-2,	 in	 B	 cells	 to	 reduced	 expression	 of	 CD19	 and	 inhibition	 of	 signaling	through	the	B	cell	receptor	(BCR)	45,46.	In	nascent	activated	memory	CD8+	T	cells,	mitochondrial	function	and	epigenetic	 remodeling	have	been	shown	 to	be	 interlinked	via	pyruvate	oxidation	and	 conversion	 of	 pyruvate-derived	 citrate	 to	 acetyl-CoA	 –	 which	 is	 required	 for	 histone	acetylation	 47,48.	 Metabolites	 of	 the	 TCA	 cycle	 can	 also	 directly	 activate	 (α-KG),	 or	 inhibit	(fumarate,	 succinate)	 dioxygenases	 that	 are	 involved	 in	 histone	 and	DNA	demethylation,	 thus	modulating	transcriptional	activity	49,50.		Indeed,	the	ratio	of	α-KG	to	[fumarate	&	succinate]	has	been	 shown	 to	 govern	 epigenetic	 changes	 and	 transcriptional	 programs	 in	macrophages	 51,52.	
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Protein	 succination	 –	 the	 fumarate-dependent,	 non-enzymatic	 addition	 of	 a	 succinyl-group	 to	thiol-groups	 in	proteins	–	provides	another	emerging	 link	between	mitochondrial	 function,	 i.e.	fumarate	production,	and	 the	 transcriptional	activity	of	 cells	 53,54.	Loss	of	 function	mutation	of	fumarase	 hydratase	 (FH)	 has	 been	 associated	 with	 decreased	 mitochondria	 respiration	 and	accumulation	of	fumarate,	which	has	been	suggested	to	post-translational	modify	kelch-like	ECH	associated	protein	1	(KEAP1)	via	succination.	Inhibition	of	KEAP1	activates	transcription	factor	nuclear	 factor,	erythroid	2	 like	2	(Nrf-2)	a	regulator	of	 inflammation	and	antioxidant	response	55,56.	 In	 theory	a	 gain	of	 function	mutation	 in	 the	SDHA	gene	 could	 also	 impact	 transcriptional	activity	 via	 succination	 by	 increasing	 endogenous	 fumarate	 levels.	 Remarkably	 SDH	 gain	 of	function	mutation	 has	 not	 yet	 been	 described,	 while	 SDH	 loss	 of	 function	mutations	 are	well	characterized	and	interlinked	with	various	diseases	affecting	tissues	with	high	energy	demands	57.		In	 macrophages	 and	 T	 cells,	 pharmacologically	 increasing	 fumarate	 levels	 has	 recently	 been	shown	to	drive	succination	events,	and	oxidative	stress	in	type	2-diabetes	has	been	described	to	lead	 to	 protein	 succination.	 In	 each	 of	 these	 scenarios	 succination	was	 demonstrated	 to	 alter	protein-,	and	thus	cellular	functions	55,58,59.	Also	numerous	mutations	in	genes	of	TCA	enzymes,	mitochondria	respiratory	chain	complexes	and	 metabolic	 check	 point	 kinases	 have	 impact	 on	 cellular	 functions	 60-62.	 Mutations	 in	mitochondrial	respiratory	complexes	have	been	linked	with	neurological	disorders,	cardiopathy	and	lactic	acidosis	61,63-65.	Mutations	in	the	isozymes	isocitrate	dehydrogenase	(IDH)	in	cancers	drive	accumulation	of	the	α-KG	analog	(R)-2-hydroxyglutarate	(R-2-HG),	which	inhibits	ATP	synthase	of	T	cells.	This	leads	to	 inhibition	 of	 T-cell	 receptor	 (TCR)	 signalling	 and	 subsequently	 to	 impaired	 activation	 and	proliferation	66.			Gain	 of	 function	 mutation	 in	 Pi(3)k–mTOR	 axis	 a	 key	 molecular	 regulator	 of	 the	 metabolic	pathway,	 results	 in	 increased	 glucose	metabolism,	 cell	 growth	 and	 proliferation	 and	 promote	lymphocyte	senescence	and	immunodeficiency	67,68.			
 In	 my	 thesis,	 I	 explored	 the	 idea	 that	 metabolic	 pathway	 activity	 of	 B	 cells	 in	 patients	 –	 or	subgroups	of	patients	–	with	antibody	deficiency	may	be	deregulated,	and	that	such	deregulated	cellular	metabolism	could	contribute	to	disease.	To	test	this	concept,	we	(i)	screened,	directly	ex	
vivo,	 the	 activity	 of	 glycolysis	 and	 mitochondrial	 respiration	 among	 B	 cells	 from	 healthy	
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individuals	 and	 patients	 with	 PAD,	 and	 (ii)	 investigated,	 in	 a	 subset	 of	 patients,	 how	 cellular	metabolism	and	B	cell	immuno-pathology	interrelated	at	the	molecular	level.	 	
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RESULTS	
B	cells	from	patients	with	primary	antibody	deficiency	have	increased	oxygen	consumption	rates.	First,	to	establish	normal	values	for	bulk	B	cell	oxygen	consumption	(oxygen	consumption	rates	–	 OCR)	 and	 glycolysis	 (extracellular	 acidification	 rates	 –	 ECAR),	 we	 measured	 both	 these	parameters	in	B	cells	from	healthy	individuals	(n	=	15)	using	a	metabolic	flux	analyzer	(Fig.	1A).	Normal	values	were	then	compared	with	those	obtained	in	patients	with	PAD	(n	=	14)	(Fig.	1A).	Antibody	deficient	patients	were	prospectively	 included	 in	 the	 study	 (inclusion	 criteria:	 age	≥	18y;	total	immunoglobulin	(Ig)	G	level	<	7g/L,	or	subclass	deficiency	(defined	as	IgG1<	4.9	g/L,	IgG2	<1.5	g/L,	 IgG3<0.2	g/L	or	IgG4<	0.08	g/L);	no	evidence	for	secondary	antibody	deficiency)	and	 metabolic	 screening	 experiments	 were	 performed	 blinded	 for	 clinical	 information.	 This	prospective	screening	approach	identified	higher	mean	respiratory	activity	(OCR)	in	B	cells	from	patients	as	 compared	 to	 the	healthy	 control	population.	Glycolysis,	by	 contrast,	was	 similar	 in	patients	 and	 controls	 (Fig.	 1A).	 Distribution	 of	 age	 was	 comparable	 between	 patients	 and	controls,	 and	 in	 either	 cohort	 no	 strong	 age	 dependence	 of	 OCR	 or	 ECAR	was	 observed	 (Fig.	
S1A).	 Also,	 no	 difference	 in	 OCR	 or	 ECAR	 was	 detected	 between	 female-	 and	 male	 study	participants,	 and	 between	 CMV+	 and	 CMV–	 individuals	 (Fig.	 S1B).	 Three	 patients	 with	 a	particularly	high	OCR	stood	out	from	this	analysis	(Patients	#1,	#8,	and	#9).	Intriguingly,	these	3	non-related	patients	were	diagnosed	with	the	same	disease,	namely	Peripheral	Polyclonal	B	Cell	
Lymphocytosis	(PPBL).	PPBL	is	a	rare	disorder,	originally	described	by	Gordon	et	al.	 in	1982	69,	characterized	by	expansion	of	B	cells	with	a	marginal	zone-like	phenotype	(CD19+	CD27+	IgD+),	bi-nucleated	 lymphocytes,	 elevated	 levels	 of	 serum	 IgM	 and	 –	 the	 inclusion	 criterion	 for	 this	study	 –	 low	 levels	 of	 IgG.	 The	 etiology	 of	 PPBL	 is	 not	 known,	 yet	 a	 genetic	 basis	 has	 been	suggested	70,71.	PPBL	is	often	clinically	silent	or	oligosymptomatic,	yet	 it	may	also	present	with	signs	 and	 symptoms	 of	 severe	 immune	 dysregulation	 and	 it	 can	 evolve	 toward	 clonal	proliferation	or	overt	malignant	lymphoma	72,73.	The	three	PPBL	patients	included	in	this	study	all	had	clinically	manifest	disease,	specifically	one	or	several	of	the	following:	bronchitis	(n	=	3),	splenomegaly	 (n	 =	 2),	 arthralgia	 (n	 =	 1),	weight	 loss	 (n	 =	 1),	 fatigue	 (n	 =	 1),	 large	 and	 small	vessel	 vasculitis,	 scleritis,	 tendinitis,	 perichondritis	 (n	 =	 1).	 Clinical	 and	 immunologic	characteristics	of	all	PAD	patients,	including	the	PPBL	patients,	are	summarized	in	Table	1A	and	
B,	respectively.	From	the	PPBL	patient	with	the	most	severe	disease	course	(Patient	#9),	Figure	
1B	is	providing	a	summary	of	C-reactive	protein	(CRP)	values	over	time	and	associated	disease	
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signs	 and	 symptoms;	 an	 example	 of	 an	 episode	 with	 cutaneous	 small-vessel	 vasculitis	(leukocytoclastic	 vasculitis),	 and	 a	 CT	 scan	 demonstrating	 periaortitis.	 In	 Figure	 1C	 a	representative	 example	 of	 the	 relative	 distribution	 of	 IgD	 vs.	 CD27	 expressing	 CD19+	lymphocytes	(i.e.	B	cells)	is	shown	from	a	healthy	control	and	one	PPBL	patient	(Patient	#8).	All	three	patients	with	PPBL	included	in	this	study	had	almost	exclusively	peripheral	blood	B	cells	with	a	marginal	zone-like	phenotype.	For	comparison,	an	example	of	flow-sorted	marginal	zone-like	 B	 cells	 (i.e.	 IgD+	 CD27+	 CD19+	 lymphocytes)	 is	 also	 shown	 (Fig.	 1C).	 To	 test	 whether	increased	respiration	was	a	general	feature	of	marginal	zone-like	B	cells,	we	compared	the	OCR	of	PPBL	B	cells	with	that	from	sorted	marginal	zone-like	B	cells	of	healthy	individuals.	The	OCR	of	 marginal	 zone-like	 B	 cells	 from	 healthy	 individuals	 was	 similar	 (or	 if	 anything	 somewhat	lower)	when	compared	to	that	of	bulk	B	cells	(Fig.	1D,	upper	left	panel).	Next,	temporal	stability	of	 hyper-respiration	 was	 determined	 by	 re-assessing	 the	 OCR	 12	 months	 after	 baseline	measurements.	 No	 change	 in	 the	 respiratory	 phenotype	 was	 observed,	 establishing	 its	robustness	 over	 time	 (Fig.	 1D,	 lower	 left	 panel).	 Hyper-respiration	 of	 PPBL	 B	 cells	 was	 also	unaffected	by	in	vivo	exposure	to	a	rapalogue	(sirolimus)	(Fig.	1E),	which	was	used	in	Patient	#9	in	 an	 (unsuccessful)	 attempt	 to	 control	 large	 vessel	 vasculitis	 	 –	 further	 pointing	 to	 a	 distinct	stability	of	 this	metabolic	phenotype.	 In	contrast	 to	mitochondrial	 respiration,	basal	glycolysis	(ECAR)	 was	 similar	 in	 PPBL	 patients	 and	 healthy	 controls,	 and	 also	 not	 different	 between	marginal	zone-like-	and	bulk	B	cell	populations	(Fig.	 1D,	upper	right	panel).	Alike	respiration,	glycolysis	–	although	being	somewhat	more	variable	than	OCR	–	was	stable	over	time	(Fig.	1D,	lower	 right	 panel).	 In	 both,	 healthy-	 and	 PPBL	 B	 cells,	 glycolysis	 similarly	 increased	 when	pharmacologically	shutting	down	mitochondrial	respiration	(data	not	shown),	as	well	as	when	stimulating	 B	 cells	 with	 IL-21	 and	 CD40L	 (Fig.	 1F).	 Lastly,	 also	 glucose	 uptake	 was	 not	consistently	different	between	healthy-	and	PPBL	B	cells	(Fig.	1G).	Of	note,	relative	distribution	of	T	cell	subpopulations	was	similar	 in	healthy	controls	and	PPBL	patients	(Fig.	 S1C).	Further,	bulk	T	cells	from	PPBL	patients	did	not	differ	in	both	OCR	and	ECAR	values	from	healthy	control	cells	 (Fig.	 S1D).	 Together	 these	 data	 identified	 hyper-respiration,	 at	 the	 cohort	 level,	 as	 an	immunometabolic	 trait	 of	 primary	 bulk	 B	 cells	 in	 patients	 with	 PAD.	 In	 the	 three	 study	participants	with	the	highest	OCR,	hyper-respiration	was	a	stable	feature	of	expanded	marginal	zone-like	B	cells	–	which	were	representing	as	much	as	90%	of	 their	peripheral	B	cell	pool	 (=	PPBL-typic).	 	
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Figure	1:	Metabolic	profile	of	healthy	controls	and	patients	with	primary	antibody	deficiency.	(A)	Basal	mitochondrial	 respiration	 (oxygen	 consumption	 rate	 –	OCR)	 (left	panel)	 and	basal	 glycolysis	 (extracellular	 acidification	rate	–	ECAR)	(right	panel)	of	B	cells	from	healthy	controls	(HCs)	(n	=	15)	and	patients	with	primary	antibody	deficiency	(PAD)	(n	=	14).	Patients	(n	=	3)	with	persistent	polyclonal	B	cell	lymphocytosis	(PPBL)	had	the	highest	OCR	values.	(B)	Upper	panel:	C-reactive	protein	(CRP)	measurements	over	time	(red	line)	and	clinical	symptoms	(red	arrows)	from	Patient	#9.	
Lower	panel:	 Left,	 histopathology	 of	 a	 skin	 biopsy,	 depicting	 leukocytoclastic	 vasculitis	 (perivascular	 neutrophilic	 infiltration	 and	nuclear	debris	(black	arrowheads),	and	deposition	of	fibrin	(red	arrowheads)).	Scale	bar,	100	μm.	Right,	abdominal	CT	scan	showing	a	contrast	enhanced	soft-tissue	dense	area	(red	arrow)	around	the	aorta,	reflecting	periaortitis.	(C)	Representative	flow	cytometry	dot	blots	showing	the	distribution	of	CD19+	B	cells	expressing	IgD	vs.	CD27	among	a	HC,	sorted	marginal	zone	(MZ)-like	B	cells	from	a	HC,	and	a	PPBL	patient.	(D)	Representative	baseline	OCR	and	ECAR	measurements	(T0)	of	primary	B	cells	or	primary	MZ-like	B	cells	from	HCs,	and	primary	B	cells	from	a	PPBL	patient.	Shown	are	basal	values	and	measurements	following	mitochondrial	perturbation	with	oligomycin	(Oli.),	FCCP,	and	rotenone	(Rot.).	Summary	bar	graphs	represent	basal	respiration	(OCR)	and	basal	glycolysis	(ECAR)	of	primary	B	cells	(n	=	4),	primary	MZ-like	B	cells	(n	=	4)	from	HCs,	and	primary	B	cells	from	PPBL	patients	(n	=	3).	Lower	panels:	Follow-up	one	year	after	baseline	assessment	(=	T12),	showing	representative	OCR	and	ECAR	measurements	of	primary	B	cells	from	a	HC	and	primary	B	cells	from	 a	 PPBL	patient.	Mitochondrial	 perturbation	was	 performed	 as	 above.	 Summary	 bar	 graphs	 represent	 T12	 basal	 respiration	(OCR)	and	T12	basal	glycolysis	(ECAR)	of	primary	B	cells	from	HCs	(n	=	3),	and	primary	B	cells	from	PPBL	patients	(n	=	3).	(E)	Mitochondrial	perturbation	profiles	of	primary	B	 cells	 from	a	HC,	 and	 from	PPBL	Patient	#9	before	 (upper	panel)	 and	during	sirolimus	(2	mg)	treatment	of	the	patient	(lower	panel	–	treatment	duration	at	the	time	of	analysis:	2.5	months).	(F)	Representative	ECAR	measurements	of	primary	B	cells	from	a	HC	and	a	PPBL	patient	before	and	following	injection	of	IL-21	plus	CD40L	directly	 into	 the	metabolic	 flux	 analyzer	 (dashed	 line).	 The	bar	 graph	 summarizes	 glycolytic	 switching,	 calculated	 as	 area	under	the	curve	(AUC)	after	activation	of	primary	B	cells	from	HCs	(n	=	3)	and	PPBL	patients	(n	=	3).	(G)	Representative	flow	cytometry	histogram,	reflecting	glucose	(2-NBDG)	uptake	of	activated	primary	B	cells	from	a	HC	and	a	PPBL	patient.	The	bar	graph	summarizes	glucose	uptake	calculated	as	geometric	mean	 fluorescence	(gMFI)	of	activated	primary	B	cells	from	PPBL	patients	(n	=	3)	relative	to	that	of	HCs	(n	=	3).	Cells	were	activated	with	IL-21	plus	CD40L	for	24	hours.	Data	are	 represented	as	mean	±	SEM.	 Statistical	 significance	was	assessed	by	one-way	ANOVA	(A),	or	unpaired	 t-test	 (D-G).	 *p	<	0.05,	**	p	<	0.01	,	***	p	<	0.001,	****	p	<	0.0001,	ns,	not	significant.	See	also	Figure	S1.			
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Table 1
A
B
IgG  g/L IgM g/L naive                          
/µl 
marginal 
zone-like 
/µl 
class 
switched       
/µl 
CD21low                 
/µl 
transitional             
/µl 
plasmablasts          
/µl 
 CD19+ CD27- 
IgD+ IgM+
CD19+ CD27+ 
IgD+ IgM+
CD19+ CD27+ 
IgD-     IgM-
CD19+ CD21low   
CD38-
CD19+ CD38+ 
IgD+ IgM+
CD19+ CD38++ 
IgD- IgM-
ref value 7-16 0.4-2.3 66-228 8-172 8-102 1-12 1-5 1-5
Pat 
1 5.9 9.04 225 2471 82 94 6 <3
2 IgG4< 0.05 2.76 128 72 28 5 6 <1
3 0.9 0.22 143 28 <1 6 2 <1
4 5.8 2.19 87 33 16 4 4 1
5 3.4 0.45 150 99 4 8 6 <1
6 4.3 0.22 95 13 2 5 <1 <1
7 6.7 0.36 244 33 9.1 3 5 <1
8 4.4 4.47 554 2168 11 39 3 <3
9 5 7.75 276 455 28 71 9 5
10 2.85 0.24 332 32 5 6 11 <1
11 3.5 1.15 81 86 11 1 1 <1
12 3.6 289 74 16 3 10 <1
13 6.3 2.21 156 92 69 2 5 <1
14 1.6 1.47 170 3 <1 40 9 <1
Pat Sex Age       at dx (y) Infection Lymphoproliferation Autoimmunity Others
1 f 46 sinusitis, bronchitis splenomegaly athralgia
2 f 45 bronchitis, pneumonia splenomegaly athralgia
3 m 21
sinusitis, bronchitis 
pneumonia
splenomegaly 
retroperitoneal 
lymphadenopathy 
vitiligo
4 f 62
postinterventional wound 
infections
5 m 58
splenomegaly, axilar 
lymphadenopathy
autoimmune 
thrombocytopenia
6 m 30 splenomegaly
autoimmune hemolytic 
anaemia
7 m 25
akne inversa, skin 
abscesses
splenomegaly atopy
8 f 51 otitis, sinusitis, bronchitis splenomegaly
exanthema, 
fatigue, 
weight loss,
9 m 54 bronchitis
perichondritis, scleritis, 
tendinis, vascultis
10 f 41
bronchitis, sinusitis, 
pneumonia
bilateral hilar 
lymphadenopathy
fatigue
11 f 35 bronchits, sinusitis diabetes mellitus 
12 f 59 bronchits, pyelonephritis psoriasis
13 f 34 autoimmune keratitis fatigue
14 f 59 bronchitis pneumonia 
retroperitoneal 
lymphadenopathy
autoimmune 
thrombocytopenia
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Mitochondrial	morphology	and	expression	of	respiratory	chain	proteins	is	normal	in	PPBL	B	cells.	Given	the	robustness	of	the	hyper-respiration	B	cell	phenotype	among	PPBL	patients,	we	went	on	to	analyze	mitochondrial	content	and	ultrastructure	of	primary	PPBL	B	cells	in	comparison	to	primary	 B	 cells	 from	 healthy	 donors.	 No	 differences	 in	 ultrastructure	 were	 identified,	 with	normal	size,	shape,	cristae	morphology,	and	matrix	morphology	of	mitochondria	in	B	cells	from	PPBL	patients.	Also	when	quantifying	cell	area;	mitochondrial	area;	number	of	mitochondria	per	cell,	and	length	over	width	(aspect	ratios),	mitochondria	of	B	cells	from	PPBL	patients	appeared	normal	 (Fig.	 2A).	 We	 then	 probed	 for	 protein	 expression	 of	 components	 of	 each	 of	 the	respiratory	chains,	specifically	NDUFB8	(complex	I),	SDHB	(complex	II),	UQCRC2		(complex	III),	COX	 II	 (complex	 IV),	 and	 ATP5A	 (complex	 V)	 in	 B	 cells	 from	 a	 healthy	 control	 and	 a	 patient.	None	of	 these	proteins	differed	 in	 abundance	between	primary	PPBL	B	 cells	 and	B	 cells	 from	healthy	 donor	 (Fig.	 2B).	 To	 more	 comprehensively	 define	 whether	 either	 abundance	 of	respiratory	chain	complexes,	or	super-complex	formation	differed	between	normal	and	PPBL	B	cells,	 blue	 native	 (BN)-PAGE	 immunoblot	 analyses	 were	 used.	 Due	 to	 limited	 availability	 of	primary	patient	material	these	experiments	were	performed	using	enriched	mitochondria	from	EBV-immortalized	 B	 cell	 lines.	 In	 both,	 healthy	 and	 PPBL	 B	 cell	 lines,	 expression	 levels	 of	complexes	I–V	were	similar.	Also,	formation	of	complex	I	containing	super-complexes	(I	plus	III,	I	plus	 III	plus	 IV),	 and	assembly	of	 complex	 III	plus	 IV	was	not	different	between	both	groups	(Fig.	 2C).	 Lastly,	 we	 also	 stained	 primary	 B	 cells	 from	 healthy	 donors	 and	 those	 from	 PPBL	patients	with	the	mitochondrial	dyes,	MTR	and	MTDR,	which	both	accumulate	dependent	upon	mitochondrial	 membrane	 potential.	 While	 mitochondrial	 abundance	 and	 morphology	 were	similar	 (Fig.	 2A),	 staining	with	 both	 dyes	was	 increased	 in	 PPBL	 B	 cells	 (Fig.	 2D).	 Increased	mitochondrial	membrane	potential	was	thus	the	sole	difference	captured	in	these	experiments	–	suggestive	 of	 a	 subtle,	 yet	 robust	 (see	Fig.	 1D),	 difference	 in	mitochondrial	 function	 that	was	driving	the	increased	OCR	of	PPBL	B	cells.		
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Figure	2:	Morphologic	and	biochemical	characterization	of	mitochondria	from	PPBL	patients.	(A)	Left	panel:	 Representative	 transmission	 electron	microscopy	 images	 of	 a	 primary	B	 cell	 from	a	HC	 and	 a	PPBL	patient.	Right	
panel:	Summary	graphs	of	cell	area;	mitochondrial	area;	mitochondria	count	per	cell,	and	mitochondrial	aspect	ratio	from	HCs	(n	=	3)	and	PPBL	patients	(n	=	3).	The	aspect	ratio	of	mitochondria	was	calculated	as	'major	axis'	over	'minor	axis'.	Between	40	and	50	B	cells	were	analyzed	per	individual.	(B)	Upper	panel:	 Immunoblot	analysis	 (total	 cell	 lysates)	of	primary	B	cells	 from	a	HC	and	a	PPBL	patient.	Blots	were	probed	 for	Complex	 I	 (CI)	 subunit	 NDUFB8,	 Complex	 II	 (CII)	 subunit	 SDHB,	 Complex	 III	 (CIII)	 subunit	 Core	 2,	 Complex	 IV	 (CIV)	 subunit	 I,	Complex	V	(CV)	ATP	synthase	subunit	alpha,	as	well	as	actin.	Lower	panel:	Quantification	of	the	abundance	of	each	complex	subunit	relative	to	actin.	(C)	Upper	panel:	Representative	blue	native	(BN)-PAGE	immunoblot	analysis	of	enriched	mitochondria	from	B	lymphoblastoid	cell	lines	 (B-LCLs)	 of	 HCs	 and	 PPBL	 patients,	 probed	 for	 CI	 (NDUFA9),	 CII	 (SDHA),	 CIII	 (UQCRC1),	 CIV	 (subunit	 I),	 CV	 (ATPB),	 and	Tomm20.	Lower	panel:	quantification	of	respiratory	complexes	and	super-complexes	(CI	plus	CIII	plus	CIV;	CIII	plus	CIV)	relative	to	Tomm20	in	enriched	mitochondria	derived	from	B-LCLs	from	HCs	(n	=	3)	and	PPBL	patients	(n	=	3).	 Individuals	were	tested	in	4	independent	experiments.	(D)	 Representative	mitotracker	 deep	 red	 (MTDR)	 and	mitotracker	 red	 (MTR)	 staining	 of	 primary	 B	 cells	 from	 a	HC	 and	 a	 PPBL	patient.	The	bar	graph	 summarizes	 the	geometric	mean	 fluorescence	 intensity	 (gMFI)	of	MTDR	and	MTR	of	primary	B	 cells	 from	PPBL	patients	(n	=	3)	relative	to	HCs	(n	=	3).	Pooled	data	are	represented	as	mean	±	SEM.	Statistical	significance	was	assessed	by	Mann-Whitney	test	(A),	unpaired	t-test	(C,D).	*p	<	0.05,	**	p	<	0.01,	ns,	not	significant.	
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Complex	II	is	hyper-functional	in	PPBL	B	cells.	With	no	evidence	for	differential	mitochondrial	abundance,	altered	mitochondrial	morphology,	or	differences	in	expression	levels-	or	interaction	of	respiratory	chain	proteins,	we	next	probed	the	function	of	each	of	the	respiratory	chain	complexes	individually.	To	that	end,	enzyme	activity	assays	and	metabolic	flux	studies	were	used,	comparing	the	respective	mitochondrial	functions	in	healthy	B	cell	 lines	and	PPBL	B	cell	 lines.	Testing	enzyme	activities	individually,	activities	of	complexes	 I,	 IV	 and	 V	 were	 identical	 in	 both	 cell	 populations.	 Activity	 of	 complex	 II	 was,	however,	 robustly	 increased	among	 the	PPBL	B	cell	 lines	 (Fig.	 3A),	providing	strong	evidence	for	a	specific	mitochondria-intrinsic	(i.e.	complex	II	intrinsic)	gain-of-function	in	these	cells.	To	test	 the	 function	 of	 the	 respiratory	 complexes	 (I–IV)	 in	 their	 normal	 structural	 context,	 their	contribution	 to	 the	 OCR	was	 assessed	 in	 permeabilized	 cells	 74.	 Also	 in	 these	metabolic	 flux-based	 studies,	 a	 selective	 increase	 in	 the	 function	 of	 complex	 II	 was	 observed	 (Fig.	 3B).	Inhibition	 of	 complex	 I	 with	 rotenone	 did	 not	 alter	 the	 difference	 of	 complex	 II-driven	respiration	 between	 B	 cell	 lines	 from	 healthy	 donors	 and	 PPBL	 patients,	 establishing	 that	increased	oxygen	consumption	was	indeed	driven	by	complex	II	activity.	Additional	immunoblot	analyses,	assessing	expression	of	Grim19,	a	subunit	of	complex	I	involved	in	electron	transfer,	as	well	 SDHA,	 a	major	 catalytic	 subunit	 of	 complex	 II,	 confirmed	 that	 protein	 abundance	did	not	differ	 between	 patients	 and	 controls	 –	 further	 pointing	 to	 complex	 II	 hyper-function	independent	of	protein	quantity	(Fig.	3D)	75,76.	Together	these	experiments	established	that	an	SDH/complex	 II	 gain-of-function	 phenotype	 was	 driving	 the	 increased	 OCR	 detected	 in	 the	screening	assays	of	the	three	patients	with	PPBL	that	were	included	in	this	study.		
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Figure	3:	Activity	of	individual	mitochondrial	respiratory	chain	complexes	in	PPBL	B	cells.	(A)	Representative	activity-assays	for	CI,	CII,	CIV,	and	CV,	depicted	as	changes	of	absorbance	over	time,	comparing	B-LCLs	from	HCs	and	PPBL	patients.	Summary	graphs	represent	activity-rates	of	individual	complexes	from	PPBL	patients	(n	=	3)	relative	to	those	of	HCs	(n	=	3-4).	(B)	Representative	OCRs	of	permeabilized	B-LCLs	from	a	HC	and	a	PPBL	patient	 following	addition	of	complex	specific	substrates	and	inhibitors,	as	indicated	(dashed	lines).	Summary	graphs	represent	changes	in	OCR	of	permeabilized	B-LCLs	from	HCs	(n	=	3-4)	and	PPBL	patients	(n	=	3).		(C)	Representative	OCRs	of	permeabilized	B-LCLs	of	a	HC	and	a	PPBL	patient,	following	addition	of	succinate,	ADP	and	rotenone	or	inhibitors,	 as	 indicated	 (dashed	 lines).	The	bar	graph	summarizes	changes	 in	OCR	of	permeabilized	B-LCLs	 from	HCs	 (n	=	3)	and	PPBL	patients	(n	=	3),	following	addition	of	CII	substrate	(succinate,	ADP)	and	subsequent	inhibition	of	CI	with	rotenone.		(D)	Representative	immunoblot	analysis	of	isolated	mitochondria	from	B-LCLs	of	a	HC	and	one	PPBL	patient.	Blots	were	probed	for	Complex	I	subunit	GRIM19,	Complex	II	subunit	SDHA,	and	Tomm20.	The	bar	graph	summarizes	the	abundance	of	Grim19	and	SDHA,	normalized	to	Tomm20,	in	isolated	mitochondria	of	B-LCLs	derived	from	HCs	(n	=	4)	and	PPBL	patients	(n	=	3).	Pooled	data	are	represented	as	mean	±	SEM.	Statistical	significance	was	assessed	by	unpaired	t-test	(A-D).	*p	<	0.05,	**	p	<	0.01,	ns,	not	significant.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		 21	
Pat Chr Basepair Ref Alt Zygosity Gene       symbol
Amino        
acid rsID ESP CADD   
Poly       
Phen2
SIFT       
score
1 5 225975 C T HET SDHA GG rs61733344 0.001 20.4 NA NA
8 5 223551 G A HET SDHA A45T rs140736646 0 23 0.002 0.16
9 5 236513 C T HET SDHA A449V rs201139275 NA 26.8 0.585 0.02
Table 2
SDHA	genetic	alterations	in	PPBL	study	participants.	To	gain	insight	into	a	possible	genetic	basis	of	the	hyper-respiration	phenotype	observed	in	the	PPBL	study	participants,	whole	exome	sequencing	(WES)	of	primary	B	cells	was	performed.	The	WES	data	were	 first	 interrogated	for	all	known	PID	mutations.	These	analyses	did	not	 identify	known	 plausible	 genetic	 abnormalities	 previously	 linked	 to	 a	 PID	 (data	 not	 shown).	We	 then	focused	 our	 investigations	 on	 rare	 genetic	 variants	 in	 genes	 encoding	 for	 mitochondrial	proteins.	This	exploration	revealed	rare	variants	with	a	high	CADD	score	in	the	SDHA	gene	of	all	three	 PPBL	 patients	 (Tbl.	 2).	 The	 same	 mutations	 were	 also	 identified	 in	 DNA	 obtained	 by	buccal	 swabs,	 suggesting	 germ-line	origin.	 Since	T	 cells	 (which	 also	harbored	 the	mutations	 –	data	 not	 shown)	 did	 not	 show	 metabolic	 alterations,	 penetrance	 of	 the	 phenotype	 was	established	as	being	highly	cell-type	specific	–	as	is	true	for	most	germ-line	genetic	diseases	77,78.		
	
	
	
	
	
	
	
	
	Pat	 	 =	 Patient;	 Chr	 =	 chromosome;	 Ref=reference	 sequence;	 Alt	 =	 alternative	 sequence;	 rsID	 =	 single	 nucleotide	 polymorphism	database	 identifier;	 ESP	 =	 Grand	 Opportunity	 Exome	 Sequencing	 Project;	 CADD	 =	 Combined	 Annotation	 Dependent	 Depletion;	PolyPhen	=	Polymorphism	Phenotyping;	SIFT	=	Sorting	Intolerant	from	Tolerant.		
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SDHA	(A45T)	interacts	more	strongly	with	SDHB	than	wild	type	SDHA.	Based	on	this	WES	derived	evidence	for	a	genetic	basis	underlying	gain-of-function	in	complex	II,	we	aimed	to	investigate	how	such	mutations	might	augment	enzyme	function	at	the	level	of	the	 protein	 structure.	 In	 a	 proof	 of	 concept	 study	 we	 focused	 our	 efforts	 on	 modeling	 the	functional	 impact	of	 the	A45T	mutation	(Patient	#8).	SDHA	catalyzes	oxidation	of	succinate	 to	fumarate	and	transfers	the	resulting	electrons	to	SDHB,	which	is	followed	by	electron	transport	to	 the	 ubiquinone	 pool	 at	 SDHC-SDHD	 (succinate	 quinone	 reductase)	 79.	 The	 SDHA-SDHB	complex	 retains	 succinate	 dehydrogenase	 activity	 also	when	 dissociated	 from	 the	membrane-anchoring	 subunits	 SDHC	 and	 SDHD	 80.	 We	 therefore	 focused	 our	 molecular	 dynamics	 (MD)	simulations	 (A45T	 vs.	wild	 type	 (wt))	 on	 the	 interaction	 between	 SDHA	 and	 SDHB.	 Since	 the	side-chain	of	Thr	is	highly	hydrophilic,	as	opposed	to	Ala,	we	postulated	that	Thr	at	position	45	forms	 hydrogen	 bonds	 with	 SDHB,	 which	 may	 stabilize	 the	 complex	 and	 favor	 the	 electron	transfer	 rate	 from	 flavin	 adenine	 dinucleotide	 (FAD)	 in	 SDHA	 to	 the	 iron-sulphur	 clusters	 in	SDHB.	 H-bonds	 between	 the	 highly	 flexible	 SDHA	 N-terminal	 segment	 and	 SDHB	 formed	randomly	 and,	 consequently,	 at	 the	 same	 rate	 in	 both	 wt	 and	 A45T	 mutated	 SDHA	 –	 with	approximately	15-20	such	events	in	each	of	~600	trajectories	that	were	analyzed	(Fig.	4A,	and	supplementary	 Video	 SV1).	 However,	 whereas	 in	 the	 scenario	 with	 the	 wt	 sequence	 these	interactions	lasted	2-3	ns	and	involved	mostly	one	atom	pair,	they	lasted	10-12	ns	and	involved	2-3	 atom-pairs	 in	 the	 case	 of	 the	 A45T	 mutation	 (Fig.	 4B,	 and	 supplementary	 Video	 SV1).	Together	 this	 resulted	 in	 a	 stronger	 hydrogen	 bond	 interaction	 between	 SDHA	 and	 SDHB	 in	presence	 of	 the	 A45T	 mutation,	 reflected	 by	 an	 increase	 in	 the	 area	 under	 the	 curve	 of	 the	hydrogen	 bonds	 between	 the	 two	 subdomains	 (Fig.	 4B).	 Residues	 1-4	 of	 the	 N-terminus	 of	SDHA	 form	 hydrogen	 bonds	with	 the	 SDHB	 loop	 connecting	 β1	 and	 β2.	 Not	 surprisingly,	 this	loop	in	SDHB	contains	a	highly	conserved	turn	formed	by	Asp20-Pro21-Asp22.	Indeed,	the	two	residues	Asp20	and	Asp22	accounted	for	more	than	90%	of	the	interactions	with	the	SDHA	N-terminal	 segment	 (Fig.	 S2A).	 Such	 a	 prototypic	 interaction,	 in	 which	 Ala1,	 Ser2	 and	 Lys4	 of	SDHA	form	hydrogen	bonds	or	salt	bridges	with	Asp20	and	Asp22	of	SDHB,	is	shown	in	Figure	
4C.	Mechanistically,	Thr	at	the	position	45	stabilized	the	SDHA-SDHB	hydrogen	bonds	by	higher	interaction	 rates	 between	Thr	 and	 residues	 on	 the	 adjacent	 surface	 of	 SDHA	 compared	 to	wt.	These	interactions,	involving	Arg458,	Phe459,	Asp511,	Arg512,	and	Met514,	maintained	the	N-terminal	 segment	 in	 a	 position	 along	 the	 surface	 of	 SDHA,	which	 favors	 the	 interactions	with	SDHB	 (Fig.	 4D).	 Informed	 by	 these	 MD	 simulation	 data	 we	 aimed	 to	 further	 experimentally	
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assess	the	impact	of	the	A45T	mutation	on	combined	SDHA	plus	SDHB	activity	(=	SDH	activity),	
in	 vitro.	 First,	 expression	 of	 mutant	 mRNA	 was	 confirmed	 in	 the	 cell	 line	 derived	 from	 the	patient	 harboring	 this	mutation	 (Fig.	 4E,	 left	 panel).	 Next	we	measured	 combined	 SDHA	plus	SDHB	activity	spectrophotometrically	in	B	cell	lines	form	Patient	#8	and	from	healthy	controls.	Indeed,	 in	 line	with	 the	MD	simulation	model,	SDH	activity	was	higher	 in	B	cell	 lines	 from	the	patient	with	the	A45T	mutation	as	compared	to	that	in	healthy	control	B	cell	lines	(Fig.	4E,	right	panel).	 These	 data	 provided	 in	 silico	 structural	 evidence	 –	 aligning	with	 in	vitro	 experimental	data	 –	 for	 a	 genetically	 imprinted	 molecular	 mechanism	 that	 drives	 excess	 function	 of	 SDH,	namely	by	increasing	interaction	between	the	SDHA	and	SDHB,	hence	facilitating	electron	flux.		
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Figure	4:	MD	simulation	of	the	interaction	between	SDHB	and	SDHA	(wt	vs.	A45T).	(A)	Number	of	hydrogen	bonds	formed	over	time	between	SDHB	and	residues	1-4	of	SDHA,	wild	type	(WT	vs.	A45T	(=	A3T	in	the	functional	protein	product).	Red	segments	highlight	the	trajectory	extract	shown	in	Video	V1	(https://www.dropbox.com/sh/cn69j7r0ropxx7t/AACgGjrcO1J9LT2UaS6lQTu1a?dl=0).Corresponding	frequency	distributions	of	the	counted	hydrogen	bonds	are	shown	in	the	insets.	(B)	Time	per	interaction	between	SDHA	and	SDHB,	calculated	as	area	under	the	curve	(AUC),	of	each	individual	simulation	replica	(WT	vs.	A45T).	(C)	Molecular	 representation	of	 the	 'SDHA	 (green)	 SDHB	 (blue)'	 complex,	 shown	 in	 ribbons.	The	prosthetic	 group	 flavin	 adenine	dinucleotide	 (FAD)	 is	 shown	as	sticks	and	CPK	coloured	(black	arrowhead).	A	 typical	 snapshot	 taken	 from	the	A45T	 trajectory	 is	shown.	Residues	of	the	N-ter	of	SDHA	within	2.5	Å	of	SDHB	are	shown	as	sticks	and	CPK	coloured.	(D)	 Time	 fraction	 of	 simulated	 contacts	 between	 Threonine	 and	 adjacent	 SDHA	 residues	 (Arg458,	 Phe459,	 Asp511,	 Arg512	 and	Met514),	as	a	percentage	of	the	SDHA–SDHB	interaction	time	in	WT	and	A45T.	(E)	Left	panel:	mRNA	 from	B	 cells	 of	 Patient	 #8,	 carrying	 the	A45T	mutation.	 Asterisk	 indicated	 changes	 of	 nucleotide	 G	 to	 A	 at	position	133.	Right	panel:	Compound	SDHA	plus	SDHB	activity	(enzyme	complex	derived	from	B-LCLs)	from	Patient	#8	relative	to	HCs	(n	=	3).	Compound	SDHA–SDHB	activity	was	independently	tested	4	times	in	both,	Patient	#8	and	each	control	subject.	Pooled	data	are	represented	as	mean	±	SEM.	Statistical	significance	assessed	by	one-way	ANOVA	(B,D),	Mann-Whitney	test	(E).	*p	<	0.05,	**	p	<	0.01,	ns,	not	significant.	See	also	Figure	S2.	
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Fumarate	accumulation	in	SDH	hyper-functional	PPBL	B	cells	is	fueled	by	glutaminolysis.	To	 gain	 insight	 into	 the	metabolic	 landscape	 of	 B	 cells	 characterized	 by	 this	 newly	 identified	'complex	 II	 gain-of-function	 phenotype',	 we	 performed	 unbiased	 metabolomic	 analyses,	comparing	 primary	 PPBL	B	 cells	with	 primary	 sorted	marginal	 zone-like	B	 cells	 from	healthy	individuals.	The	key	finding	of	these	experiments	was	a	strong,	and	statistically	highly	significant	accumulation	of	fumarate,	i.e.	the	direct	product	of	SDH.	Malate,	the	first	downstream	metabolite	of	SDH	in	the	TCA	cycle	(=	product	of	fumarate	hydratase),	was	also	much	more	abundant	(Fig.	
5A,	 left	 panel)	 81.	With	 the	 noticeable	 exception	 of	 succinate,	 all	 other	 TCA	 cycle	metabolites	captured	 in	 this	 assay	were	 –	 albeit	 to	 a	 lesser	 extent	 than	 fumarate	 and	malate	 –	 also	more	abundant	 in	 PPBL	B	 cells	 than	 in	 healthy	marginal	 zone-like	B	 cells	 (Fig.	 5A,	 left	 panel).	 This	metabolite	 profile	 was	 in	 line	 with	 the	 increased	 functional	 activity	 of	 SDH	 identified	 in	 the	previous	 experiments	 (Figs.	 3,4).	 Since	 glutamate	 and	 α-KG	 were	 further	 significantly	 more	abundant	 in	 PPBL	 B	 cells,	 the	metabolomic	 data	were	 suggesting	 increased	 glutaminolysis	 in	PPBL	B	 cells	 as	 compared	 to	healthy	marginal	 zone-like	B	 cells	 (Fig.	 5A,	 left	 and	 right	panel).	Several	 glycolytic	 intermediates	were	 also	more	 abundant	 in	 PPBL	 B	 cells	 (dihydroxyacetone	phosphate,	 2-phosphoglycerate,	 phosphoenolpyruvate	 and	 lactate).	 This	 was	 pointing	 to	increased	 glycolysis	 in	 PPBL	 B	 cells	 –	 which	 was,	 however,	 not	 sufficiently	 pronounced	 to	consistently	drive	increased	ECAR	values	(Fig.	1A,D,F)	and	was	also	not	associated	with	a	more	pronounced	uptake	of	glucose	(Fig.	 1G).	Of	note,	whereas	the	ratio	of	succinate	over	 fumarate	was	 increased	 in	 PPBL	 B	 cells,	 the	 ratio	 of	α-KG	 to	 [fumarate	 &	 succinate]	 was	 not	 different	between	PPBL	B	cells	and	healthy	marginal	zone-like	B	cells	since	α-KG	was	also	more	abundant	in	 these	 cells	 (Fig.	 5B).	 To	 directly	 compare	 contribution	 of	 glucose-	 vs.	 glutamine-derived	carbons	to	TCA	cycle	metabolites,	metabolic	tracing	studies	were	performed	on	primary	PPBL	B	cells,	 using	 uniformly	 labeled	 13C-glucose	 and	 13C-glutamine,	 respectively	 (Fig.	 5C).	 These	studies	were	informative	in	three	ways.	First,	glutamine	was	found	to	significantly	contribute	to	the	 fueling	of	 the	TCA	 cycle	 (abundant	m+5	α-KG;	m+4	 succinate,	m+4	 fumarate,	m+4	malate	and	m+4	citrate).	Also	at	the	glutamine-derived	m+2	level	(suggestive	of	more	than	one	round	of	TCA	cycling	in	the	case	of	glutamine),	glutamine	and	glucose	similarly	contributed	to	the	pool	of	
α-KG,	 succinate,	 fumarate	 and	malate.	 Glutamine	 thus	 was	 an	 important	 TCA	 fuel	 source	 for	PPBL	 B	 cells.	 Second,	 the	 presence	 of	 m+5	 citrate	 pointed	 to	 reductive	 carboxylation	 of	glutamine-derived	 α-KG	 as	 an	 anaplerotic	 source	 in	 PPBL	 B	 cells.	 Third,	 as	 also	 seen	 in	 the	untargeted	 metabolomic	 analyses,	 we	 observed	 low	 m+2;	 m+4	 succinate	 levels	 followed	 by	
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increased	 m+2;	 m+4	 fumarate-	 and	 malate	 levels,	 both	 when	 considering	 glucose-derived	 or	glutamine-derived	 carbons.	 Combined	 these	 metabolomic	 and	 tracing	 studies	 (i)	 identified	glutamine	as	an	important	fuel	source	and	an	anaplerotic	source	of	the	TCA	cycle	in	PPBL	B	cells,	and	(ii)	confirmed	accumulation	of	fumarate	(and	malate)	–	as	a	result	of	hyperactive	SDH	(Figs.	
3,4).		
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Figure	5:	Metabolic	characterization	of	PPBL	B	cells.	(A)	Left	panel:	Significant	fold	change	of	glycolysis	and	the	TCA	cycle	metabolites	between	primary	B	cells	from	PPBL	patients	(n	=	3)	and	primary	MZ-like	B	cells	 from	HCs	(4	samples	pooled	of	n	=	7	donors).	Right	panels:	Relative	abundance	of	glycolysis	and	TCA	cycle	metabolites	in	primary	MZ-like	B	cells	from	HCs	and	primary	B	cells	from	PPBL	patients	(donors	as	in	left	panel).	(B)	Ratio	of	abundance	of	α-ketoglutarate	over	(succinate	+	fumarate),	and	ratio	of	the	abundance	of	fumarate	over	succinate,	both	in	primary	MZ-like	B	cells	from	HCs	and	primary	B	cells	from	PPBL	patients	(donors	as	in	(A)).	(C)	Metabolic	tracing	analysis	of	primary	B	cells	from	PPBL	patients	(n	=	3)	incubated	for	6	hours	with	13C-glucose	or	13C-glutamine.	Bar	graphs	show	distribution	of	mass	isotopomers,	the	scheme	depicts	the	primary	labelling	of	glucose-	and	glutamine-derived	13C	fuelling	into	the	TCA	cycle.	Pooled	data	are	shown	as	mean	±	SEM.	Statistical	significance	was	assessed	by	Welch's	two	sample	t-test	(A),	unpaired	t-test	(B),	and	one-way	ANOVA	(C).	*p	<	0.05,	**	p	<	0.01,	***	p	<	0.001,	****	p	<	0.0001,	ns,	not	significant.	
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PPBL	B	cells	have	an	inflammatory	transcriptional	profile.	Having	 characterized	 the	 metabolic	 alteration	 and	 fuel	 usage	 of	 PPBL,	 we	 went	 on	 and	investigated	 the	 transcriptional	 profile	 of	 primary	 PPBL	 B	 cells	 in	 comparison	 to	 their	metabolically	 non-affected	 counterpart,	 i.e.	 marginal	 zone-like	 B	 cells	 from	 healthy	 blood	donors.	Of	 the	13’107	gene	 transcripts	 that	were	expressed,	mRNA	abundance	of	1’878	genes	(14.33%)	 differed	 in	 a	 statistically	 significant	 manner	 between	 the	 groups.	 Unsupervised	hierarchical	 clustering	of	 the	 samples	 revealed	 two	groups	corresponding	 to	PPBL	B	cells	and	healthy	marginal	 zone-like	B	 cells	 (Fig.	 6A).	 Establishing	 their	 close	 relationship,	 both	 groups	were	characterized	by	a	gene	profile	typically	found	in	marginal	zone-like	B	cells	(Fig.	6B)	82,83.	mRNA	abundance	of	metabolic	genes,	i.e.	those	involved	in	glycolysis,	glutamine	metabolism	and	the	TCA	cycle,	were	similar	in	primary	patient	B	cells	and	healthy	marginal	zone-like	B	cells	(Fig.	
6C,	 left	 panel,	 and	Fig.	S3A).	Of	 note,	 also	 transcript	 levels	 of	mitochondrial	 complex	 II	 genes	were	similar	(Fig.	6C,	right	panel),	as	were	those	encoding	for	proteins	in	the	other	respiratory	complexes	(Fig.	S3B).		In	 sharp	 contrast,	 gene	 products	 annotated	 to	 the	 inflammatory	 response,	 and	 the	 IL-6–Jak–Stat3	 pathway,	 were	 enriched	 in	 the	 PPBL	 sample	 (Fig.	 6D).	 Among	 the	 most	 differentially	regulated	inflammatory	gene	product	was	IL-6,	a	classic	B	cell	cytokine,	but	also	transcripts	for	TNF,	 IL-8,	CCL5	and	IL-1β	were	more	abundantly	expressed	in	PPBL	B	cells	(Fig.	 6D,E).	These	cytokines	have	been	described	 as	being	produced	by	marginal	 zone-like	B	 cells,	 reflecting	 the	innate-like	 function	 of	 these	 cells	 as	 sensors	 of	 danger	 and	 regulators	 of	 the	 early	 immune	response	84-86	83,87-91.	From	a	clinical	perspective,	PPBL	manifestations,	particularly	in	Patient	#9,	pointed	 to	 the	 relevance	 of	 IL-6	 (trigger	 of	 CRP	 production	 by	 hepatocytes)	 and	 IL-8	 (key	neutrophil	chemoattractant)	(specifically:	chronic	elevation	–	and	intermittent	spiking	–	of	CRP	levels;	propensity	for	acute	sterile	inflammation	mediated	by	neutrophils	(polychondritis,	small	vessel	vasculitis	('leukocytoclastic	vasculitis'))	(Fig.	1B,	Tbl.	1A)	92-94.	Indeed,	IL-6	and	IL-8	were	also	 increased	 at	 the	 protein	 level,	 both	 in	 the	 supernatant	 of	 non-activated	 as	 well	 as	 in	activated	B	cell	lines	from	PPBL	patients,	when	compared	to	marginal	zone-like	B	cell	lines	from	healthy	blood	donors	(Fig.	6F).	Production	of	IL-8	by	PPBL	B	cells	was	much	more	variable	than	that	of	IL-6,	and	less	affected	by	stimulation	with	IL-21	and	CD40L	(Fig.	6F).		
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Figure	6:	Transcriptional	profile	of	PPBL	B	cells.	(A)	Hierarchical	clustering	(heatmap)	of	sample	correlation	and	MA	plot	of	 transcriptome	data	 from	primary	MZ-like	B	cells	 from	HCs	(n	=	4)	and	primary	B	cells	form	PPBL	patients	(n	=	3).	(B)	mRNA	abundance	of	MZ-like	B	cell	marker-genes	in	primary	MZ-like	B	cells	from	HCs	and	primary	B	cells	 form	PPBL	patients	(donors	as	in	(A)).	(C)	Heatmap	of	relative	expression	of	genes	involved	in	the	TCA	cycle-	(left	panel)	and	genes	encoding	complex	II	(right	panel),	 in	primary	MZ-like	B	cells	from	HCs	and	primary	B	cells	form	PPBL	patients	(donors	as	in	(A)).	(D)	 Gene	 set	 enrichment	 analysis	 (GSEA)	 of	 inflammatory-response	 genes	 (left	 panel)	 and	 IL-6-Jak-Stat3	 pathway	 genes	 (right	
panel),	transcribed	in	primary	B	cells	from	PPBL	patients,	compared	to	MZ-like	B	cells	from	HCs	(donors	as	in	(A)).	(E)	 Heatmap	 of	 pro-inflammatory	 cytokine	 genes	 in	 primary	 MZ-like	 B	 cells	 from	 HCs	 and	 primary	 B	 cells	 form	 PPBL	 patients	(donors	as	in	(A)).	(F)	Production	of	IL-6	and	IL-8	protein	by	MZ-like	B-LCLs	from	HCs	(n	=	3)	and	B-LCLs	from	PPBL	patients	(n	=	3).	Cytokines	were	quantified	in	culture	supernatants	of	non-activated	cells,	or	cells	activated	with	IL-21	plus	CD40L	for	48	hours.	Experiments	were	performed	3-4	times.	Pooled	data	are	shown	as	mean	±	SEM.	Statistical	significance	was	assessed	by	unpaired	t-test	(F).	*p	<	0.05,	**	p	<	0.01.	See	also	
Figure	S3.	
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Fumarate	accumulation	can	drive	an	inflammatory	PPBL	B	cell	phenotype.	Given	the	inflammatory	transcriptome,	and	cytokine	output,	of	PPBL	B	cells,	we	aimed	to	assess	whether	hyperactive	SDH	and	increased	cytokine	production	were	linked.	First,	we	probed	the	effect	of	the	SDH	inhibitor	3-nitropropionic	acid	(3-NPA)	on	mitochondrial	respiration	and	IL-6	production.	Increased	OCR	of	PPBL	B	cell	lines	was	efficiently	reduced	by	inhibiting	SDH	with	3-NPA,	 both	 in	 intact	 cells	 (Fig.	 7A),	 and	 in	 isolated	 mitochondria,	 i.e.	 in	 permeabilized	 cells	provided	with	succinate	and	ADP	(Fig.	 7B).	 Importantly,	both	basal	 secretion	as	well	as	 IL-21	plus	CD40L	driven	production	of	IL-6,	was	diminished	in	PPBL	B	cell	lines	in	the	presence	of	3-NPA	 (Fig.	 7C).	A	 genetic	 SDHA	knockdown	 system	was	 then	utilized	 to	 specifically	 define	 the	impact	 of	 SDH	 activity	 (more	 precisely	 the	 impact	 of	 the	 flavoprotein	 subunit	 of	 SDH	 that	 is	responsible	 for	 transferring	 electrons	 from	succinate	 to	 coenzyme	Q	 (succinate	+	 a	quinone	=	fumarate	 +	 a	 quinol))	 on	 production	 of	 IL-6.	 SDHA-targeting	 siRNA	 reduced	 SDHA	 protein	expression-levels	by	approximately	40%	(Fig.	7D),	which	was	sufficient	to	reduce	OCR	of	PPBL	B	 cell	 lines	 by	 around	 50%	 (Fig.	 7E).	 Reduced	 SDHA	 activity	 was	 consistently	 linked	 with	diminished	 IL-6	 production	 in	 PPBL	 B	 cell	 lines	 from	 all	 three	 patients	 (Fig.	 7F).	 These	experiments	established	that	SDHA	in	PPBL	B	cells	was	associated	with	their	increased	output	of	IL-6.	The	data,	however,	did	not	clarify	whether	an	SDHA	intrinsic	feature,	or	the	product	of	SDH	
per	 se,	 i.e.	 fumarate,	were	 linked	 to	 the	 inflammatory	 output	 of	 PPBL	 B	 cells.	 To	 address	 this	issue	we	genetically	reduced	expression	of	fumarate	hydratase,	the	enzyme	downstream	of	SDH	converting	 fumarate	 to	 malate,	 in	 marginal	 zone-like	 B	 cell	 lines	 from	 healthy	 blood	 donors.	Knockdown	efficiency	in	these	experiments	was	around	25%	(Fig.	7G),	which	was	sufficient	to	measurably	increase	fumarate	abundance	in	these	cells	(Fig.	7H).	In	cell	lines	with	high	baseline	production	 of	 IL-6,	 genetically	 engineering	 endogenous	 fumarate	 accumulation	 was	 indeed	sufficient	to	enforce	increased	spontaneous	production	of	IL-6	(Fig.	7I).	These	experiments	thus	identified	 fumarate	 accumulation	 as	 an	 inflammatory	 trigger	 in	 healthy	 marginal	 zone-like	 B	cells	with	high	baseline	IL-6	production.	At	the	same	time,	accumulation	of	malate	–	which	was	also	 observed	 in	 PPBL	 B	 cells	 with	 hyperactive	 SDH	 –	was	 ruled	 out	 to	 be	 necessary	 for	 the	inflammatory	activity	observed	in	PPBL	B	cells.		
Fumarate	drives	succination	of	KEAP1	and	Nrf-2	dependent	transcription	of	IL-6.	Next	we	aimed	to	mechanistically	link	fumarate	accumulation	and	inflammatory	reprogramming	of	marginal	zone-like	B	cells.	Both	succinate	and	fumarate	have	been	assigned	important	roles	in	
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balancing	the	activity	of	α-KG	in	its	function	as	activator	of	histone	and	DNA	demethylases.	49,50.	Increased	 expression	 of	 genes	 involved	 in	 histone	 demethylation	 has	 been	 linked	 with	augmented	 cytokine	 production	 in	 monocytes	 cultured	 with	 fumarate	 51.	 To	 test	 whether	 in	PPBL	B	cells	a	similar	 transcriptional	response	was	 induced	by	 fumarate,	we	related	the	PPBL	transcriptomes	 with	 the	 publically	 available	 fumarate-driven	 transcriptome	 of	 monocytes	 51.	Gene	 expression	 profiles	 did,	 however,	 not	 correlate	 between	 these	 cell	 types	 (Fig.	 7J).	 To	screen	for	gross	alterations	of	histone	methylation,	pan-H3	methylation	was	assessed	between	healthy	primary	B	cells	and	primary	PPBL	B	cells.	In	line	with	our	finding	that	the	ratio	between	
α-KG	 and	 [succinate	 &	 fumarate]	was	 not	 altered	 between	 these	 two	 cell	 types	 (Fig.	 5B),	 no	difference	 in	 pan-H3	methylation	 was	 detected	 (Fig.	 7K).	 Irrespective	 of	 abundance	 of	 other	TCA	metabolites,	succination	of	proteins	by	fumarate	has	been	shown	to	alter	protein	function	in	macrophages	and	T	cells,	as	well	as	non-immune	cells	58,59,95.	Using	an	antibody	recognizing	the	stable	adduct	formed	by	succination,	i.e.	S-2-(succino)cysteine	(2SC),	we	went	on	and	compared	the	 protein	 succination	 profile	 of	 healthy	 primary	 B	 cells	 and	 primary	 PPBL	 B	 cells.	 Indeed,	succination	was	more	pronounced	in	PPBL	B	cells,	with	the	most	prominent	band	appearing	at	the	size	of	64	kD	(Fig.	7L).	In	cancer	cells	with	loss-of-function	mutations	in	fumarate	hydratase,	and	 consecutive	accumulation	of	 fumarate,	 succination	of	Kelch-like	ECH	Associated	Protein	1	(KEAP1)	has	been	described	55,96.	Notably,	KEAP1	has	an	apparent	molecular	mass	of	60-64	kD	in	 SDS-PAGE	 run	 under	 reducing	 conditions.	 A	 direct	 consequence	 of	 KEAP1	 succination	 is	stabilization	 of	 the	 transcription	 factor	 nuclear	 factor	Nrf-2,	with	 consecutive	 transcription	 of	Nrf-2	regulated	genes.	Given	 the	paucity	of	primary	patient	material	we	were	so	 far	unable	 to	directly	 define	 the	 nature	 of	 this	 64	 kD	 protein	 by	 e.g.	 mass	 spectrometry.	 However,	 when	stripping	blots	 and	 re-staining	with	a	monoclonal	 antibody	against	KEAP1,	 a	band	at	 the	very	same	position	was	consistently	revealed,	highly	suggestive	of	KEAP1	being	succinated	in	PPBL	B	cells	(Fig.	7L).	To	directly	probe	whether	Nrf-2,	released	by	succinated	KEAP1,	did	regulate	the	production	 of	 the	 inflammatory	 cytokines	 IL-6	 and	 IL-8	 in	 PPBL	 B	 cells,	 the	 small	 molecule	inhibitor,	ML-385,	was	utilized.	ML-385	 is	a	 recently	developed,	highly	 specific	Nrf-2	 inhibitor	that	 is	 being	 investigated	 for	 use	 in	 patients	 suffering	 from	 cancers	 with	 loss-of-function	mutations	 in	 KEAP1,	 or	 gain-of-function	 mutations	 in	 Nrf-2	 97-99.	 Effectively,	 both	 in	 non-activated	 and	–	 even	more	pronounced	 so	 –	 in	 activated	PPBL	B	 cells,	ML-385	 led	 to	 reduced	production	of	both	IL-6	and	IL-8	(Fig.	7M).	These	data	indicated	that	the	inflammatory	output	of	PPBL	B	cells	was	controlled	in	an	Nrf-2	dependent	manner.	
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In	 all,	 a	 molecular	 framework	 thus	 emerged	 with	 hyperactive	 SDH	 driving	 accumulation	 of	fumarate,	which	in	turn	led	to	succination	of	KEAP1	and	subsequent	Nrf-2	driven	inflammatory	reprogramming	of	marginal	zone-like	B	cells.	 	
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Figure	7:	SDHA	activity	and	inflammatory	cytokine	production.	(A)	 Representative	 mitochondrial	 perturbation	 profile	 of	 B-LCLs	 from	 a	 PPBL	 patient	 incubated	 with	 the	 SDHA	 inhibitor	 3-nitropropionic	acid	(3-NPA),	or	left	untreated,	for	12	hours	prior	to	the	experiment.	The	bar	graph	summarizes	basal	mitochondrial	respiration	of	B-LCLs	from	PPBL	patients	(n	=	3)	either	exposed,	or	not	exposed,	to	3-NPA.	(B)	Representative	mitochondrial	respiration	profile	of	permeabilized	B-LCLs	from	a	PPBL	patient	prior	to	and	following	addition	of	complex	 II	 specific	 substrates	 (succinate,	ADP)	and	 the	SDHA	 inhibitor,	malonate,	as	 indicated	 (dashed	 lines).	B-LCLs	were	either	exposed,	or	not	exposed,	to	3-NPA	for	12	hours	prior	to	the	assay.	The	bar	graph	summarizes	changes	in	OCR	of	permeabilized	B-LCLs	from	PPBL	patients	(n	=	3),	following	addition	of	CII	substrate	(succinate,	ADP)	and	subsequent	inhibition	either	exposed,	or	not	exposed,	to	3-NPA.	(C)	Production	of	 IL-6	by	B-LCLs	 from	PPBL	patients	 (n	=	3),	measured	 in	 the	 culture	 supernatant	of	non-activated	cells,	 or	 cells	activated	with	IL-21	plus	CD40L,	in	the	presence	or	absence	of	3-NPA	for	48	hours.	IL-6	ratios	were	calculated	relative	to	baseline	(untreated	cells).	IL-6	production	from	each	PPBL	patients	was	tested	2-3	times.	(D)	Immunoblot	analysis	of	total	cell	lysates	from	B-LCLs	of	PPBL	patients	(n	=	3)	transfected	with	control	si-RNA,	or	SDHA	si-RNA,	and	probed	for	SDHA	protein	abundance.	The	bar	graph	summarizes	knockdown	efficiency	from	(n	=	6)	independent	experiments.	(E)	Representative	mitochondrial	respiration	profile	of	permeabilized	B-LCLs	from	a	PPBL	patient	prior	to	and	following	addition	of	complex	II	specific	substrates	and	the	SDHA	inhibitor,	malonate,	as	indicated	(dashed	lines).	B-LCLs	were	treated	with	either	control	si-RNA	or	SDHA	si-RNA	prior	to	the	assay.	The	bar	graph	summarizes	changes	in	OCR	of	permeabilized	control	si-RNA	or	SDHA	si-RNA	treated	B-LCLs	from	PPBL	patients	(n	=	3).	(F)	Production	of	 IL-6	by	B-LCLs	 from	PPBL	patients	 (n	=	3)	was	quantified	 in	 cell	 culture	 supernatants	of	 cells	 that	were	either	treated	with	control	si-RNA	or	SDHA	si-RNA	for	48	hours.	Each	patient	cell	line	was	tested	2	times.	(G)	Representative	 immunoblot	probing	for	 fumarate	hydratase	 in	total	cell	 lysate	 from	MZ-like	B-LCLs	of	a	HC	transfected	either	with	control	si-RNA	or	FH	si-RNA.	The	bar	graph	summarizes	knockdown	efficiency	from	(n	=	6)	independent	experiments.	(H)	Production	of	IL-6	by	MZ	like	B-LCLs	from	HCs	(n	=	3)	was	quantified	in	cell	culture	supernatants	of	cells	transfected	with	either	control	si-RNA	or	FH	si-RNA	for	48	hours.	(I)	Fumarate	abundance	in	MZ	like	B-LCLs	from	HCs	(n	=	3)	transfected	with	either	control	si-RNA	or	FH	si-RNA	for	48	hours.	Each	cell	line	was	tested	2-3	times.	(J)	Comparison	of	genes	that	were	differentially	expressed	between	non-treated	and	fumarate-treated	monocytes	(y-axis)	and	those	differentially	expressed	between	primary	MZ-like	B	cells	from	HCs	(n	=	4)	and	primary	B	cells	from	PPBL	patients	(n=3)	(x-axis)	51.	(K)	Representative	 immunoblot	probing	 for	histone	H3	methylation	among	primary	B	cells	of	 a	HC	vs.	primary	B	cells	of	 a	PPBL	patient.	The	bar	graph	summarizes	data	from	HCs	(n=3)	and	PPBL	patients	(n	=	3).	(L)	Representative	immunoblot	analyses	probing	primary	B	cells	of	HC	and	PPBL	patients	for	S-(2-succino)cysteine	(2sc),	followed	by	stripping	and	re-staining	for	KEAP1.	The	bar	graph	represents	quantification	of	2sc	abundance	at	64kD	in	primary	B	cells	of	HCs	(n	=	3)	and	PPBL	patients	(n	=	3).	(M)	Production	of	IL-6	and	IL-8	by	B-LCLs	from	PPBL	patients	(n	=	3),	measured	in	the	culture	supernatant	of	non-activated	cells,	or	cells	activated	with	IL-21	plus	CD40L,	in	the	presence	or	absence	of	the	NRf-2	inhibitor,	ML-385,	for	48	hours.	Each	patient	cell	line	was	tested	2-3	times	(exception:	IL-8:	only	tested	once	for	each	patient	cell	line).	Pooled	 data	 are	 shown	 as	mean	 ±	 SEM.	 Statistical	 significance	was	 assessed	 by	 paired	 t-test	 (A,B,D-I),	 unpaired	 t-test	 (K,L)	 and	Wilcoxon	signed	rank	test	(C,M).	*p	<	0.05,	**	p	<	0.01.	
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DISCUSSION	
The	potential	of	quantifying	cellular	metabolic	pathway-activities	as	 'functional	biomarkers'	of	cellular	pathology	has	not	been	previously	explored.	Here,	in	a	prospective	screening	approach,	mitochondrial	respiration	was	found	to	be	higher	in	B	cells	from	PAD	patients.	In	the	subset	of	patients	with	the	most	pronounced	respiratory	phenotype	this	observation	guided	the	discovery	of	 a	 new	 class	 of	 immune-pathologic	 deregulation,	 driven	 by	 fumarate	 accumulation.	Specifically,	 hyper-respiration	 due	 to	 SDH	 gain-of-function	 was	 identified	 as	 the	 primary	metabolic	 derangement	 causative	 of	 fumarate	 accumulation,	 protein	 succination	 and	inflammatory	reprogramming	of	marginal	zone-like	B	cells	 in	 three	 independent	patients	with	PPBL.	Whether,	 and	 if	 so,	how	 hyper-respiration	 in	 other	 PAD	patients	 contributes	 to	 specific	disease	phenotypes	remains	to	be	defined.	In	principle,	excess	mitochondrial	function	may	link	with	immunopathology	in	many	ways,	ranging	from	disrupted	redox	balance	or	inadequate	ROS	production	to	altered	acetylation	reactions;	deregulation	of	epigenetic	modifiers	and	–	in	light	of	the	findings	from	this	report	–	pathogenic	succination	events	35,55,96,100,101.		Notably,	 gain-of-function	 mutations	 in	 proteins	 of	 the	 respiratory	 chain	 have	 not	 been	previously	reported	–	making	the	here-described	SDHA	phenotype,	and	in	particular	the	W45T	mutation	that	we	have	characterized	in	detail,	the	first	of	its	kind.	Of	note,	in	marginal	zone-like	B	cells,	chronic	fumarate-driven	production	of	IL-6	–	a	key	B	cell	growth	factor–	may	contribute,	in	 addition	 to	 driving	 disease-typic	 B	 cell	 lymphocytosis,	 to	 the	 increased	 risk	 for	 B	 cell	lymphoma	noted	 in	 these	patients	 21,72,102-104.	 If	 indeed	overshoot	 SDH	 function	were	 linked	 to	tumorigenesis,	 this	 would	 assign	 this	 enzyme	 both	 tumor	 suppressing	 and	 tumor	 promoting	properties,	since	SDH	–	alike	several	of	the	respiratory	complex-encoding	gene	products	–	also	has	 tumor	 suppressor	 properties	 49,105-107.	 Opportunities	 to	 therapeutically	 target	 overshoot	mitochondrial	function	may	emerge	from	this	insight.	In	the	case	of	patients	with	SDHA-driven	fumarate	 accumulation	 as	 the	metabolic	 cause	 for	 inflammatory	 reprogramming,	 repurposing	drugs	 utilized	 in	 cancer	 patients	might	 become	 an	 opportunity.	 Ionidamine,	 for	 example,	 is	 a	well-tolerated	 compound	 that	 has	 been	 shown	 to	 inhibit	 succinate-ubiquinone	 reductase	activity	 of	 complex	 II	 without	 fully	 blocking	 enzymatic	 activity	 108,109.	 In	 case	 of	 succination-dependent	 activation	 of	 the	 KEAP1–Nrf-2	 axis,	 Nrf-2	 inhibitors	 might	 prove	 successful	 97-99.	However,	 since	 the	 KEAP1–Nrf-2	 axis	 is	 driving	 cell-type	 specific	 transcriptional	 responses,	mildly	 targeting	 the	 enzyme	 causative	 for	 fumarate	 accumulation	might	more	 precisely	 affect	dysregulated	transcriptional	responses	of	marginal	zone-like	B	cells	110.	
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Cell	 type	 specificity	 was	 indeed	 highlighted	 by	 a	 recent	 report	 that	 demonstrated,	 in	 LPS-stimulated	macrophages,	 that	 itaconate	–	via	alkylation	of	KEAP1	–	drives	an	Nrf-2	dependent	
anti-inflammatory	program	 in	 these	 cells.	 In	 contrast	Nrf-2	mediated	 enhanced	 activity	 of	 the	inflammasome	has	been	reported	in	stimulated	bone	marrow	derived	macrophages	111.	Aligning	with	 this	 finding	 several	 reports	 have	 shown	 that	 Nrf-2	 deficiency	 alleviates	 pathogenesis	 of	atherosclerosis,	diabetes	mellitus	and	obesity	112-114.	The	importance	of	tight	regulated	Nrf-2	has	been	 shown	 in	 a	 colitis	 model.	 Here	 overexpression	 of	 Nrf-2	 in	 epithelial	 and	 myeloid	 cells	exacerbates	induced	acute	colitis,	whereas	chronic	colitis	was	little	affected	by	deregulated	Nrf-2	115.	Nrf-2	 is	 a	 pleiotropic	 transcription	 factor,	 which	 not	 only	 regulates	 inflammation	 but	 also	antioxidant	response,	proliferation	and	differentiation	116.	 In	several	cancer	types	up	regulated	Nrf-2	expression	has	been	linked	with	an	uncontrolled	proliferation	and	cancer	progress	117-119.	Whether	 fumarate	 driven	 Nrf-2	 activation	 is	 in	 involved	 in	 the	 pathogenesis	 of	lymphoproliferation	in	PPBL	cells	has	to	be	subject	of	further	research.			The	 KEAP1–Nrf-2	 system	 thus	 may	 emerge	 as	 a	 highly	 cell-type	 specific	 immunometabolic	sensing	system,	integrating	distinct	metabolic	activities	with	immunologic	output.		It	 is	 intriguing	 to	note	 that	 in	multiple	 sclerosis	 and	psoriasis,	 fumarate-esters	 are	being	used	clinically	 for	 their	 anti-inflammatory	 properties	 120-122.	 In	 macrophages	 and	 T	 cells,	pharmacologically	 increasing	 fumarate	 levels	 has	 recently	 been	 shown	 to	 drive	 succination	events,	 including	 at	 the	 catalytic	 site	 of	 GAPDH	 59.	 Succination	 of	 GAPDH	 was	 found	 to	 curb	aerobic	glycolysis	 in	 these	cells	–	 thereby	mediating	anti-inflammatory	activity	 59.	By	contrast,	we	now	found	that	in	PPBL	B	cells,	endogenous	accumulation	of	fumarate	–	via	inadequate	SDH	activity	–	led	to	succination	of	KEAP1,	which	drove	a	pro-inflammatory	transcriptional	program.	As	glycolysis	was	not	 the	major	driver	of	 the	 inflammatory	output	 in	 these	 cells,	PPBL	B	 cells	would	thus	be	predicted	to	evade	GAPDH-directed	anti-inflammatory	activity	of	fumarate-esters.	In	fact,	exposure	of	PPBL	patients	to	fumarate-esters	might	exacerbate	inflammation.		This	highlights	the	granularity	of	immunometabolic	regulation	and	underscores	the	importance	of	understanding,	in	much	detail,	the	distinct	metabolic	repertoires	of	immune	cell	subsets	as	we	move	towards	clinical	metabolic	interventions.		
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In	mice,	marginal	zone	B	cells	are	innate-like	cells	with	the	capacity	to	rapidly	mount	a	first-line	immune	 defensive	 response.	 As	 such	 these	 cells	 are	 poised	 to	 quickly	 produce	 a	 plethora	 of	inflammatory	cytokines.	In	humans,	IgD+	CD27+	B	cells	are	the	assumed	counterparts	of	rodent	marginal	zone	B	cells	83,123.	While	the	precise	functional	relevance	of	human	marginal	zone-like	B	cells	 remains	 unclear,	 they	 also	 rapidly	 produce	 inflammatory	 cytokines	 upon	 stimulation	 82.	Aligning	 with	 the	 clinical	 phenotype	 of	 the	 PPBL	 patients	 in	 this	 study,	 mild	 fumarate	accumulation	in	these	inflammation-prone	cells	did	drive	non-regulated	inflammatory	cytokine	output.	 Also	 when	 not	 intrinsically	 reprogrammed	 to	 produce	 inadequate	 amounts	 of	inflammatory	 cytokines,	 marginal	 zone	 B	 cells	 have	 been	 shown	 to	 contribute	 to	immunopathology.	Specifically,	IL-6	produced	by	marginal	zone	B	cells	has	been	demonstrated	to	exacerbate	experimental	systemic	inflammatory	responses	91.	It	is	further	interesting	that	also	in	 the	 context	 of	 autoimmunity,	 such	 as	 Sjogren's	 syndrome,	marginal	 zone	B	 cells	 have	 been	proposed	to	contribute	to	disease	124,125.		Whether	metabolic	 deregulation	 plays	 a	 role	 in	 the	 inadequate	 activation	 of	marginal	 zone	B	cells	in	autoimmunity	remains	to	be	determined.		In	 each	 of	 the	 study	 participant	 with	 PPBL	 the	 genetic	 analysis	 identified	 a	 rare	 germline	mutation	 in	 SDHA.	 All	 three	 individuals	 carried,	 however,	 different	 mutations.	 For	 the	 A45T	mutation	 we	 provide	 a	 detailed	 structural	 model	 aligning	 with	 the	 experimentally	 observed	gain-of-function	(Fig.	4).	In	silico,	the	Thr	at	position	3	of	the	A45T-mutated	SDHA	contributed	to	only	a	small	amount	of	inter-domain	contacts,	which	did	not	support	the	hypothesis	of	a	direct	interaction	between	this	residue	and	SDHB	as	the	mechanism	causing	the	enhanced	interactions	observed	between	the	two	proteins.	One	can	speculate	that	a	mechanism	involves	hydration	of	the	 N-terminus	 of	 SDHA.	 The	 higher	 hydrophilic	 nature	 of	 Thr,	 as	 compared	 to	 Ala,	 might	increase,	 locally,	 the	 hydration	 level	 of	 the	 neighboring	 residues,	 thus	 stabilizing	 hydrophilic	interactions	 between	 the	 SDHA	 N-terminal	 and	 the	 SDHB	 loop.	 This	 mechanism	 would	 be	analogous	to	the	driving	force	of	protein	folding	nucleation	126.	The	third	mutation,	rs61733344,	was	 synonymous.	The	 rs61733344	mutation	was	not	 in	 a	 splice	 site	 and	 it	 did	not	detectably	affect	 protein	 expression	 (Fig.	 2C,	 3D).	 Synonymous	 mutations	 were	 long	 believed	 to	 be	functionally	neutral.	However,	there	is	increasing	evidence	to	the	contrary.	Indeed	codon	usage	bias,	 i.e.	unequal	frequency	at	which	synonymous	codons	are	found,	has	been	demonstrated	in	most	genomes	at	above	random	levels	127.	Importantly,	synonymous	rare	codons	have	also	been	
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shown	 to	 play	 important	 functional	 roles	 in	 e.g.	 regulation	 of	 co-translational	 folding	 and	covalent	modifications,	in	vivo	128.	While	much	remains	to	be	learned	about	the	molecular	events	that	 connect	 synonymous	 codon	 usage,	 protein	 biogenesis	 and	 cell	 physiology,	 the	 here	identified	 mutation	 might	 be	 subject	 to	 one	 such	 mechanism.	 The	 functional	 and	 clinical	importance	 of	 synonymous	mutations	 in	 human	 disease	 is	 underscored	 by	 the	 fact	 hat	more	than	 50	 human	 pathologies	 firmly	 associate	with	 them,	 and	 that	 –	 overall	 –	 non-synonymous	and	synonymous	mutations	have	a	similar	probability	of	associating	with	disease	129,130.		In	summary,	instructed	by	metabolic	screening	this	study	identified	SDHA	gain-of-function	as	a	novel	 primary	 immune	 dysregulation,	 driving	 fumarate-dependent	 succination	 and	inflammatory	reprogramming	of	marginal	zone-like	B	cells.	Representing	the	first	example	of	a	
primary	 retrograde	 signaling	 pathology	 (i.e.	 disruption	 of	 mitochondria-to-cellular-transcriptional	regulation),	our	data	point	to	therapeutic	repurposing	strategies	by	uncovering	druggable	targets	–	namely	SDHA,	Nrf-2	and	IL-6	–	along	this	dysregulated	molecular	axis.		
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MATERIALS	AND	METHODS	
Study	subjects	The	study	was	approved	by	 the	Ethikkommission	Nordwest-	und	Zentralschweiz;	 approval	 code	EKNZ	 2015-187.	 Fourteen	 patients,	 and	 15	 age	 and	 sex	 matched	 healthy	 controls,	 were	prospectively	 recruited	between	 July	2015	and	December	2016.	 Inclusion	 criteria	 for	patients	were	as	follows:	age	>18	years;	serum	IgG	level	<7g/l,	or	IgG	subclass	deficiency	(IgG1	<4.9	g/l,	IgG2	 <1.5	 g/l,	 IgG3	<0.2	 g/l,	 IgG4	<0.08	 g/l).	 Patients	 evaluated	 by	 a	 Clinical	 Immunologist	 and	classified	as	with	a	form	of	secondary	antibody	deficiency	were	excluded	from	the	study.		
Blood	sample	phenotyping	and	immunoglobulin	quantification	After	written	informed	consent,	blood	samples	from	patients	and	healthy	controls	(blood	donor	center,	University	Hospital	Basel)	were	obtained.	From	all	patients	a	differential	white	blood	cell	count,	including	total	lymphocyte	as	well	as	T	and	B	cell	numbers,	were	obtained.	B	cells	(CD19+	in	 lymphocyte	 gate)	 were	 further	 phenotyped	 as	 follows:	 naïve	 B	 cells	 (IgD+	 CD27–	 IgM+),	marginal	zone-like	B	cells	(IgD+	CD27+	IgM+),	memory	B	cells	(IgD–	CD27+	IgM–),	 transitional	B	cells	(IgD+	IgM+	CD38+),	CD21	low	B	cells	(CD21low	CD38–),	and	plasmablasts	(IgD–	IgM–	CD38++).	T	cells	 (CD3+	 in	 lymphocyte	gate)	were	classified	 into:	CD4+	T	cells,	CD8+	T	cells,	naïve	 (CD27+	CD45RO–)	 vs.	 central	 memory	 (CD27+	 CD45RO+)	 vs.	 effector	 memory	 (CD27–	 CD45RO+/–).	Further,	serum	levels	of	total	IgG	and	IgG	subclasses	(IgG1-4);	IgM;	IgA,	and	IgE	were	quantified.	All	above	experiments	were	performed	at	the	GMP-certified	central	laboratory	of	the	University	Hospital	Basel.		
Cell	sorting	To	isolate	immune	cell	subsets,	peripheral	blood	mononuclear	cells	(PBMCs)	were	first	isolated	by	 standard	 density-gradient	 centrifugation	 (Lymphoprep	 Fresenus	 Kabi,	 Norway).	 B	 cells	(CD19+)	and	T	cells	(CD3+)	were	then	positively	selected	using	magnetic	beads	(Miltenyi	Biotec,	Germany)	 according	 to	manufacturer’s	 instructions.	 For	 isolation	of	marginal	 zone-like	B	 cells	(MZ-like	B	 cells),	 B	 cells	 (CD19+)	were	 stained	with	 anti-CD27	brilliant	Violet	 605	 (Biolegend,	USA)	and	anti-IgD	VioBlue	(Miltenyi	Biotec)	mAb.	CD19+CD27+IgD+	B	cells	were	sorted	with	a	BD	Influx	cell	sorter	(BD	Bioscience,	USA).	Prior	to	downstream	experiments,	cells	were	rested	for	3	
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hours	 in	 RPMI-1640	 medium	 (GIBCO,	 USA)	 containing	 10%	 fetal	 bovine	 serum	 (FBS,	 GIBCO,	USA),	50U/ml	penicillin	and	50	μg/ml	streptomycin	(GIBCO)	(R10-FBS)	at	37°C.	
	
EBV	transformed	B	lymphocyte	cell	lines	PBMCs	or	sorted	MZ-like	B	cells	were	 incubated	with	EBV-containing	supernatant	 from	B95-8	cells	for	1	hour	and	additionally	stimulated	with	CpG	(1	μg/ml).	Cyclosporine	A	(1	μg/ml)	was	added	weekly	 for	 a	 total	 of	 four	weeks	 to	 eliminate	 T	 cells.	 Purity	 of	 EBV	 transformed	 B	 cell	lines,	as	defined	by	flow	cytometry,	was	92-98	%	(CD19+	and	CD3–).		
Metabolic	flux	analysis	A	Seahorse	XF-96e	extracellular	 flux	analyzer	(Seahorse	Bioscience,	Agilent	Technologies,	USA)	was	used	to	define	cellular	oxygen	consumption	rates	(OCR)	and	extracellular	acidification	rates	(ECAR).	 Cells	were	 plated	 (3x105	 cells/well)	 onto	 plates	 coated	with	 Cell-Tak	 (Corning,	 USA).	Mitochondrial	perturbation	experiments	were	carried	out	by	sequential	addition	of	oligomycin	(1	 μM,	 Sigma-Aldrich,	 USA),	 FCCP	 (2	 μM,	 Carbonyl	 cyanide	 4-(trifluoromethoxy)	phenylhydrazone,	 Sigma-Aldrich),	 and	 rotenone	 (1	 μM,	 Sigma-Aldrich).	 OCR	 and	 ECAR	 were	monitored	 in	 real	 time	 after	 injection	 of	 each	 compound.	 Basal	 respiration	was	 calculated	 by	subtracting	non-mitochondrial	respiration	(rotenone	rate)	from	baseline	rate	47.	For	measuring	activation-induced	 glycolytic	 activity,	 primary	 B	 cells	 were	 activated	 with	 IL-21	 (200	 ng/ml,	ImmunoTools,	Germany)	and	CD40L	(200	ng/ml,	Sigma-Aldrich)	injected	into	the	flux	analyzer	via	 injection	 ports,	 and	 ECAR	 was	 monitored	 in	 real	 time.	 For	 monitoring	 OCR	 of	 intact	mitochondria	only,	cells	were	resuspended	in	MAS	buffer	(70	mM	sucrose,	220	mM	mannitol,	10	mM	 KH2PO4,	 5	 mM	MgCl2,	 2	 mM	 HEPES,	 and	 1	mM	 EGTA),	 then	 treated	 with	 the	 XF	 plasma	membrane	permeabilizer	 (Seahorse,	Agilent	Technologies),	which	was	 followed	by	addition	of	with	pyruvate	(5	mM)	/	malate	(2.5	mM)	/	ADP	(1	mM)	and	rotenone	(1	μM)	for	monitoring	CI-driven	respiration;	succinate	(10	mM)	/	ADP	(1	mM)	with/without	rotenone	(1	μm	/	2	μm)	and	malonate	(0.04	mM)	for	monitoring	CII-driven	respiration;	duroquinol	(0.5	mM)	/	ADP	(1	mM)	and	antimycin	A	(0.02	mM)	for	monitoring	CIII-driven	respiration;	TMPD	(0.5	mM)	/	Ascorbate	2	mM)	/	ADP	(1	mM)	and	sodium	azide	(20	mM)	(all	 from	Sigma-Aldrich)	 for	monitoring	CIV-driven	respiration.	Changes	in	OCR	upon	substrate	addition	were	calculated	relative	to	the	pre-injection	rate.	Changes	in	OCR	upon	inhibitor	addition	were	calculated	relative	to	the	substrate	rate.	
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2-NBDG	uptake	To	 assess	 glucose-uptake,	 5x105	 primary	 B	 cells	 were	 activated	 with	 IL-21	 (200	 ng/ml,	ImmunoTools)	and	CD40L	(200	ng/ml,	Sigma-Aldrich)	for	24	hours.	Cells	were	then	incubated	in	medium	containing	20	μM	2-NBDG	(Invitrogen)	for	45	min	and	analyzed	by	flow	cytometry.		
Mitotracker	red	and	mitotracker	deep	red	Primary	B	cells	were	incubated	for	20	min	at	37°C	/	5%	CO2	with	100	nM	Mitotracker	red	(MTR,	Invitrogen),	or	100	nM	Mitotracker	deep	red	(MTDR,	Invitrogen),	respectively.	Cells	were	then	washed	 twice	 in	 staining	 buffer	 (PBS	 plus	 1%	 bovine	 serum	 albumin)	 and	 analyzed	 by	 flow	cytometry.		
Activity	of	individual	respiratory	chain	complexes	To	 measure	 the	 activity	 of	 individual	 mitochondrial	 respiratory	 chain	 complexes,	 ELISA	microplate	 assay	kits	 (Abcam,	UK)	were	used	according	 to	 the	manufacturer’s	 instructions.	 In	brief,	 CI	 activity	 was	 analyzed	 by	 tracking	 oxidation	 of	 NADH;	 CII	 by	 via	 the	 production	 of	ubiquinone;	CIV	by	tracing	oxidation	of	cytochrome	c;	CV	by	assessing	conversion	of	ATP	to	ADP	and	the	coupled	oxidation	of	NADH.		
Electron	microscopy	Transmission	 electron	 microscopy	 was	 performed	 at	 the	 Biozentrum	 (University	 of	 Basel).	Primary	B	cells	were	sequentially	fixed	in	3%	paraformaldehyde,	0.5%	glutaraldehyde	and	1%	osmium	 tetraoxide,	 embedded	 and	 then	 cut	 into	 60	 nm	 sections.	 Micrographs	 (27’000x	magnification)	 were	 obtained	 with	 a	 Morgagni	 268	 (FEI,	 Hillsboro	 OR,	 USA)	 transmission	electron	 microscope	 operated	 at	 80	 kV.	 ImageJ	 software	 (NIH,	 Bethesda,	 USA)	 was	 used	 for	measuring	 cell	 area;	 mitochondrial	 area,	 and	 mitochondrial	 length	 (major	 axis)	 and	 width	(minor	axis).	The	aspect	ratio	of	mitochondria	was	calculated	as	‘major	axis’	over	‘minor	axis’,	an	aspect	ratio	of	1	indicating	a	circular	mitochondrial	section.	
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Blue	native	PAGE	For	 isolation	 of	mitoplasts,	 8	 x	 106	 B-LCLs	were	 re-suspended	 in	 100	 μl	 of	 PBS,	 32.5	 μl	 of	digitonin	(8	mg/ml)	was	added	and	cells	were	 incubated	on	 ice	 for	10	min.	Cold	PBS	(1	ml)	was	added	and	cells	were	centrifuged	for	5	min	at	10’000	x	g.	The	pellet	was	resuspended	in	100	μl	of	AA	buffer	(500	mM	6-aminohexanoic	acid,	50	mM	immidazole,	1	mM	EDTA,	pH	7)	and	10	μl	of	a	10%	digitonin	solution	was	added.	Next,	 cells	were	centrifuged	 for	30	min	at	18’000	 x	 g.	 Supernatant	 was	 harvested	 and	 10	 μl	 of	 sample	 buffer	 (5%	 blue	 G-250,	 5%	glycerol	 in	 AA	 Buffer)	 was	 added.	 Samples	 were	 stored	 at	 −80°C	 until	 use.	 BN-PAGE	 was	performed	as	described	 131.	Membranes	were	probed	 for	anti-NDUFA9	mAb	(20C11B11B11,	Abcam),	 anti-complex	 II	 70	 kDA	 Fp	 mAb	 (459200,	 Invitrogen),	 Anti-	 UQCRC1	 mAB	(16D10AD9AH5)	 (110252,	 Abcam),	 anti-oxphos	 Complex	 IV	 Subunit	 I	 mAb	 (459600,	Invitrogen),	 anti-ATPB	 antibody	 [3D5]	 -	 Mitochondrial	 Marker	 mAb	 (14730,	 Abcam)	 and	Tom20	(FL-145)	(sc11415,	Santa	Cruz	Biotechnology,	USA).	 	 	For	densitometry	analysis,	 the	ImageJ64	 software	 was	 used.	 Band	 limits	 were	 determined	 using	 low-exposure	 images	 to	efficiently	distinguish	individual	bands.		
Isolation	of	mitochondria	Cell	pellets	were	washed	with	cold	PBS	and	 lysed	using	RIPA	buffer	(Thermo	Fisher	Scientific,	Rockford	 IL,	 USA)	 containing	 protease	 and	 phosphatase	 inhibitors	 (Roche,	 Switzerland).	 To	prepare	mitochondrial	fractions,	3x107	B-LCLs	were	collected	and	washed	with	buffer	A	(83	mM	sucrose,	10	mM	MOPS,	pH	7.4).	Cell	pellets	were	then	homogenized	with	20	strokes	in	a	tightly	fitting	glass-teflon	homogenizer	with	1	ml	of	buffer	B	(buffer	A	plus	10mM	triethanolamine,	5%	percoll,	0.01%	digitonin,	proteaseinhibitor,	pH	7.4).	Nuclei	and	unbroken	cells	were	removed	by	centrifugation	at	2’500	x	g	for	5	min.	Supernatants	were	collected	and	centrifuged	at	10’000	x	g	for	15	min.	Mitochondria	were	then	suspended	in	an	appropriate	volume	of	buffer	C	(300	mM	sucrose,	EGTA	1	mM,	20mM	MOPS,	proteaseinhibitor,	pH	7.4)	for	storage	at	−80°C	until	use.		
Immunoblot	analysis	Protein	 concentrations	were	 determined	 by	 BCA	 protein	 assay	 kit	 (Thermo	 Fisher	 Scientific).	Whole-cell	 lysates	or	mitochondrial	 fractions	were	 separated	by	4-15%	Mini	Protean	TGX	Gel	(Bio-Rad,	Hercules	CA,	USA),	and	transferred	to	nitrocellulose	using	Trans-Blot	Turbo	Transfer	
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(Bio-Rad,	Hercules	CA,	USA).	Membranes	were	probed	with	anti-Grim19	mAb	(ab110240),	anit-NDFU8	 mAb	 (ab110242),	 anti-SDHB	 mAb	 (ab14714),	 anti-Complex	 III	 subunit	 Core	 2	 mAb	(ab14745),	anti-Complex	IV	subunit	II	mAb	(ab110258)	and	anti-ATPα	mAb	(ab14748)	(all	from	Abcam),	 anti-SDHA	 mAb	 (119989),	 anti-FH	 mAb	 (4567),	 anti-KEAP1	 mAb	 (8047),	 anti-NRF2	pAb	(12721),	pan-methyl-histone	H3	(Lys9)	mAb	(4473)	and	anti-β-actin	mAb	(3700)	(all	from	Cell	 Signaling,	 USA)	 and	 anti-2SC	 pAb	 (crb2005017e,	 Cambridge	 Research	 Biochemicals,	 UK).	Blots	 were	 then	 stained	 with	 the	 appropriate	 secondary	 antibody	 (IRDye	 800CW-conjugated	goat	 polyclonal	 antibody	 against	 rabbit	 IgG	 (926-32211)	 or	 RDye	 800CW-conjugated	 goat	polyclonal	antibody	against	mouse	IgG	(926-32219)	from	LI-COR).	The	Odyssey	imaging	system	(LICOR)	was	used	for	detection,	and	the	ImageJ	software	(1.48v)	for	quantification.		
13C6	glucose	and	13C6	glutamine	labeling	Primary	B	cells	(2x106)	from	patients	were	plated	onto	48	well	plates	in	RPMI10-FBS	with	4	mM	U-13C	glucose	or	4	mM	U-13C	glutamine	for	6	hours.	Metabolites	were	extracted	with	50	%	MeOH	/	 30	 %	 Acetonitrile.	 Isotopologue	 distribution	 was	 assessed	 by	 LC-MS.	 Metabolites	 were	extracted	 from	 cells	 using	 ice-cold	 80	 %	 methanol,	 followed	 by	 sonication	 and	 removal	 of	cellular	 debris	 by	 centrifugation	 at	 4°C.	 Metabolite	 extracts	 were	 dried,	 derivatized	 as	 tert-butyldimethylsilyl	 (TBDMS)	 esters,	 and	 analyzed	 via	 GC-MS	 as	 previously	 described	 132.	Uniformly	 deuterated	 myristic	 acid	 (750	 ng	 /	 sample)	 was	 added	 as	 an	 internal	 standard	following	 cellular	metabolite	 extraction,	 and	metabolite	 abundance	was	 expressed	 relative	 to	the	 internal	 standard,	 and	 normalized	 to	 cell	 number.	 Mass	 isotopomer	 distribution	 was	determined	using	a	custom	algorithm	developed	at	McGill	University,	Canada	133.		
Metabolomics	Cell	pellets	from	primary	patient	B	cells	and	primary	MZ-like	B	cells	from	healthy	controls	were	isolated	as	described	above,	washed	twice	with	cold	PBS,	snap	frozen	in	EtOH	containing	dry	ice	and	 stored	 at	 −80°C.	 Metabolomic	 assays	 and	 analysis	 were	 performed	 by	 Metabolon	 Inc.	(Durham,	USA).		
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RNA	sequencing	RNA	from	primary	patient	B	cells	and	primary	MZ-like	B	cells	from	healthy	controls	was	isolated	using	 nucleospin	 RNA	 kit	 (Macherey-Nagel,	 Germany)	 following	 manufacturer’s	 instructions.	RNA-seq	was	performed	by	Admera	Health	(USA).	In	brief,	samples	were	isolated	using	ethanol	precipitation.	 Quality	 check	 was	 performed	 using	 Tapestation	 RNA	 HS	 Assay	 (Agilent	Technologies,	USA)	and	quantified	by	Qubit	RNA	HS	assay	(Thermo	Fisher	Scientific).	Ribosomal	RNA	 depletion	 was	 performed	 with	 Ribo-zero	 Magnetic	 Gold	 Kit	(MRZG12324,	 Illumina	 Inc.,	USA).	 Samples	 were	 randomly	 primed	 and	 fragmented	 based	 on	 manufacturer’s	recommendation	 (NEBNext®	 Ultra™	 RNA	 Library	 Prep	 Kit	 for	 Illumina®).	 First	 strand	 was	synthesized	 using	 Protoscript	 II	 Reverse	 Transcriptase	 with	 a	 longer	 extension	 period	 (40	minutes	 for	 42°C).	 All	 remaining	 steps	 for	 library	 construction	 were	 used	 according	 to	 the	NEBNext®	Ultra™	 RNA	 Library	 Prep	 Kit	 for	 Illumina®.	 Illumina	 8-nt	 dual-indices	were	 used.	Samples	were	pooled	and	sequencing	on	a	HiSeq	with	a	read	length	configuration	of	150	paired-end.		
Whole	exome	sequencing	The	 Oragene	 DNA	 OG-500	 kit	 (DNA	 Genotek	 Inc.,	 Canada)	 was	 used	 to	 collect	 saliva	 from	patients,	 DNA	 was	 extracted	 using	 PrepIT	 L2P	 reagent	 (DNA	 Genotek	 Inc.).	 Whole	 exome	sequencing	(WES)	was	performed	on	B	cells,	T	cells	and	saliva	of	all	3	PPBL	patients	included	in	this	study.	The	input	DNA	concentration	was	200	ng.	DNA	was	quality	controlled	using	Genomic	DNA	 ScreenTape	 System	 (200	 bp	 to	 60000	 bp)	 on	 a	 TapeStation	 2200	 (both	 Agilent	Technologies).	Sonication	with	a	Covaris	E220	was	used	to	achieve	fragmentation	to	150-200bp.	Sonication	 as	 well	 as	 library	 preparation	 was	 performed	 using	 the	 SureSelectXT	 Target	Enrichment	System	for	Illumina	Paired-End	Sequencing	Library	Protocol	(Version	C0,	December	2016).	SureSelectXT	Reagent	kits	were	used	for	library	preparation	(Agilent	Technologies).	Exon-specific	 biotinylated	 oligonucleotides,	 SureSelect	 Human	 All	 Exon	 V6	 (Agilent	Technologies),	 were	 hybridized	 with	 the	 samples.	 Exons	 were	 pulled	 down	 using	 Dynabeads	MyOne	 Streptavidin	 T1	 magnetic	 beads	 (Thermo	 Fisher	 Scientific,).	 Paired-end	 125	 bp	sequencing	was	performed	on	HiSeq	4000	 Illumina	platform.	Output	 files	 from	 the	 sequencer	were	 in	 FASTQ	 format.	 Paired-end	 sequencing	 resulted	 in	 two	 FASTQ	 files	 for	 each	 sample,	forward	 and	 reverse.	 Forward	 and	 reverse	FASTQ	 files	were	 aligned	 to	 the	 reference	 genome	(hg19)	 using	 Burrows-Wheeler	 Aligner	 (BWA_MEM).	 The	 output	 of	 BWA	 was	 a	 sequence	
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alignment	map	(SAM)	file.	Picard	tools	v2.7.1	(Picard_Tools_v2.7.1)	was	used	to	make	a	binary	version	of	SAM	files	(=BAM	files).	Quality	control	was	performed	as	per	Genome	Analysis	Tool	Kit	 (GATK)	 v3.5	 guidelines	 from	 Broad	 Institute	 134.	 Each	 output	 BAM	 file	 was	 individually	analyzed	for	variants	from	the	reference	genome	using	HaplotypeCaller	from	GATK	resulting	in	a	variant	called	file	(VCF).	Annotation	of	mutations	was	performed	using	Combined	Annotation	Dependent	Depletion	(CADD	v1.3)	and	Variant	effect	predictor	(VEP)	programs	135,136.	Mutations	of	 interest	 were	 visualized	 in	 silico	 using	 the	 Integrative	 Genomics	 Viewer	 (IGV)	 in	 order	 to	confirm	 the	mutation	was	 in	 fact	 somatic	 and	 not	 present	 in	 controls	 129,137.	 The	 synonymous	mutation	was	 further	 investigated	 for	 splice	 altering,	miRNA	site,	 or	mRNA	structure	 altering,	using	 NNSplice	 (NNSplice_v0.9),	 Human	 Splicing	 Finder	 (Human_Splice_Finder_v3.1),	TargetScan	 (Target_Scan_v7.1)	 and	 Rescue	 ESE	 (RESCUE-ESE)	 138,139.	 Somatic	 analysis	 was	performed	 using	 VarScan	 v2.3.9,	 Strelka	 Somatic	 Caller	 and	MuTect2	 140,141	 142.	 Annotation	 of	somatic	 mutations	 from	 the	 3	 callers	 was	 performed	 using	 CADD	 v1.3	 and	 VEP	 programs.	Somatic	mutations	were	visualized	in	silico	using	IGV.	
	
End	point	PCR	Primers	for	the	SDHA	isoform	as,	forward	'GCA	TTT	GGC	CTT	TCT	GAG	GC'	,	reverse	'	GCA	CAG	TCA	GCC	TCG	TTC	AA'	 ;	 and	 for	 the	 SDHA	mutation	 as,	 forward	 '	 CGA	CTC	CGG	CGT	GGT	G'	 ,	reverse	'	CTG	CAA	CAG	TGT	GTG	ACC	TG'	were	designed	according	the	ncbi	primer	blast	webtool	(https://www.ncbi.nlm.nih.gov/tools/primer-blast/).	 PCR	 was	 run	 using	 Go	 Taq	 G2	 DNA	Polymerase	(Promega,	USA)	with	a	GoTaq	Green	Master	Mix	(Promega)	and	the	fragments	were	amplified	 in	 a	 thermal	 cycler	 (Professional	 Trio	 Thermocycler,	 Thermo	Fisher	 Scientific).	 PCR	products	were	 separated	in	 a	 1.5%	agarose	 gel	 and	purified	using	Qiaquick	Gel	 Extraction	Kit	(QIAGEN,	Germany).	
	
Construction	of	human	SDHA	and	SDHB	structures	Interaction	between	SDHA	and	SDHB	were	studied	using	MD	simulations.	To	date	no	structures	of	 human	 SDHA	 or	 SDHB	 have	 been	 published,	 yet	 the	 crystal	 structure	 of	 porcine	 heart	mitochondrial	complex	II	has	been	solved	at	3.1	Å	resolution	(PDB	code	4YTP)	143.	Porcine	SDHA	shares	94.58%	protein	identity	with	its	human	homolog	(P31040),	and	the	porcine	and	human	SDHB	 proteins	 share	 high	 sequence	 homology	 as	 well.	 To	 generate	 a	 model	 of	 the	 human	SDHA/SDHB	complex,	the	sequence	of	the	protein,	as	obtained	from	the	US	National	Centre	for	
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Biotechnology	Information	(https://www.ncbi.nlm.nih.gov	-	accessed	22nd	February	2018),	was	submitted	 to	 the	 automated	 protein	 structure	 homology-modeling	 server,	 SWISS-MODEL	 144.	Using	 the	 VMD	 and	 Chimera	 suites,	 a	 complex	 of	 human	 SDHA	 and	 SDHB	 was	 designed	 as	follows:	the	N-ter	SDHA	segment	was	generated	and	grafted	onto	the	SDHA	structure	as	well	the	C-ter	and	both	termini	of	SDHB	145	 146.	Using	VMD,	the	20	residues	of	 the	porcine	SDHA/SDHB	that	differ	 from	the	human	protein	were	changed	 into	the	corresponding	human	counterparts.	Finally,	 two	 different	 models	 were	 generated,	 each	 extended	 at	 the	 N-ter	 with	 segments	 of	sequence	 ASAKVSDSI	 (wt)	 and	 ASTKVSDSI	 (A3T	 =	 A45T	mutation),	 respectively	 145.	 The	 A3T	numbering	 refers	 to	 the	 functional	 protein,	 i.e.	 not	 including	 the	 transit	 peptide,	 which	 is	removed	 during	 post-translational	 processing	 147.	 SDHA	 contains	 the	 prosthetic	 group	 flavin	adenine	 dinucleotide	 (FAD),	 SDHB	 three	 iron-sulphur	 clusters.	 The	 structure	 of	 FAD	 was	obtained	 from	 the	 Zinc	 library	 and	 their	 parameters	 were	 obtained	 through	 the	 CHARMM	General	Force	Field	(CGenFF)	version	1.0.0	148,149.	To	study	the	SDHA/SDHB	interaction,	the	FAD	prosthetic	group	and	the	residues	 located	in	the	cores	of	the	subdomains	were	simulated	with	position	 restraints	 (with	 a	 force	 constant	 of	 400	 kJ	mol–1	 nm–2).	 The	 proteins,	 including	 FAD,	were	virtually	inserted	in	a	water	box,	and	K+	and	Cl–	ions	added	to	simulate	a	physiological	ionic	concentration	of	150	mM,	and	their	respective	number	set	to	neutralize	the	system.	Simulations	were	conducted	with	 the	GROMACS	package,	version	2016.3,	using	parallel	 tempering	 150.	The	CHARMM36	 topology	 and	parameter	 files	were	used	 to	 represent	 the	protein	 	 and	water	was	represented	 by	 the	 TIP3P	model,	 whereas	 parameters	 for	 FAD	 were	 calculated	 with	 CGenFF	148,151.	 The	 calculation	 of	 the	 electrostatic	 forces	 utilized	 the	 Particle-Mesh	 Ewald	 summation	method,	with	a	 cutoff	of	12	Å	 for	 the	 real	 space	 interactions,	 a	1.2	Å	grid	and	4th	order	 spline	interpolation	for	the	reciprocal	space.	The	Lennard-Jones	short	and	long-range	cutoffs	were	set	to	 12	 Å	 and	 10	 Å,	 respectively.	 Isotropic	 pressure	 at	 1	 bar	was	 virtually	maintained	 through	coupling	to	a	Parrinello-Rahman	barostat,	with	a	virtual	compressibility	of	4.5	x	10–5	bar	and	a	coupling	 time	 of	 5	 ps	 152.	 Prior	 to	 the	 simulations,	 the	 systems	were	minimized	with	 steepest	descent.	In	order	to	further	equilibrate	the	systems	and	allow	water	molecules	to	relax,	a	25	ps	simulation	 with	 a	 time	 step	 of	 1	 fs	 and	 with	 position	 restraints	 on	 the	 protein	 atoms	 was	performed	(with	a	force	constant	of	400	kJ	mol–1	nm–2).	For	parallel	tempering,	an	ensemble	of	48	temperatures	in	the	range	310-385K	was	generated,	whereas	solute	and	solvent	were	weakly	coupled	 to	Nose-Hoover	 thermostats	with	 coupling	 times	 of	 1	 ps	 153,154.	 Bonds	with	 hydrogen	atoms	 were	 constraint	 using	 the	 LINCS	 algorithm	 allowing	 usage	 of	 a	 time	 step	 of	 2	 fs.	 An	
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interval	of	0.4	ns	was	set	 for	 the	exchange	probability	calculation,	 thus	providing	enough	time	for	 SDHA-SDHB	 interactions	 to	 occur	 155.	 Each	 individual	 trajectory	 was	 ~22.5-23.0	 ns	 long,	totalizing	 1100	 and	 1080	 ns	 for	 the	 wt	 and	 the	 A3T	 mutant,	 respectively.	 The	 trajectories	simulated	 for	 at	 a	 temperature	 lower	 than	 360K	were	 retained	 for	 the	 analyses,	 which	were	conducted	 either	 on	 the	 statistical	 platform	R	 and	 specific	R	 packages,	 GROMACS	 tools,	 or	 in-house	 Python	 scripts	 156.	 The	 readHBmap.py	 script	 was	 used	 to	 extract	 the	 hydrogen	 bond	existences	from	the	hydrogen	bond	Map	files.		
SDH	activity	SDH	activity	(i.e.	compound	activity	of	SDHA	and	SDHB)	was	measured	spectrophotometrically	from	the	reduction	of	2,6-diclorophenol-indophenol	(DCPIP)	by	tracking	the	absorbance	at	600	nm	over	3	min.	 Frozen	B-LCLs	 (5	 x	 106)	were	 thawed	 and	 resuspended	 in	 100	μl	 PBS	on	 ice,	protein	 concentration	 was	 determined,	 and	 the	 volume	 was	 adjusted	 to	 the	 sample	 with	 the	lowest	 concentration.	 Each	 sample	 (20	 μl)	was	 suspended	 in	 950	 μl	 of	 buffer	 C1/C2	 (25	mM	potassium	 phosphate	 (K2HPO4)	 (pH	 =	 7.2),	 5	 mM	 MgCl2,	 3	 mM	 KCN,	 2.5	 mg/ml	 BSA)	supplemented	with	100	mM	succinate	 and	0.1%	Triton	X-100,	 and	 incubated	10	min	 at	 room	temperature.	After	 addition	of	6	μl	 5	mM	DCPIP,	 2	μl	 1	mg/ml	of	 antimycin	A	 and	2	μl	 1	mM	rotenone,	samples	were	incubated	for	2	min.	Then,	6	μl	of	10	mM	phenazine	methosulfate	(PMS)	was	 added	 and	 absorbance	 was	 measured.	 Compound	 activity	 of	 SDHA	 and	 SDHB	 was	extrapolated	using	the	following	formula:	[SDH	activity	=	((rate/min)/19.1)	/	sample	volume	x	1000	x	dilution	factor],	where	19.1	is	the	molar	extinction	coefficient	at	30°C	(mM−1	cm−1).		
Cytokine	measurements	B-LCLs	(4	x	106)	 from	patients,	and	MZ-like	B-LCLs	from	healthy	controls,	were	plated	 into	48	well	plates.	Cells	were	either	left	unstimulated	(non-activated	controls),	or	activated	with	IL-21	(40	 ng/ml,	 ImmunoTools)	 and	 CD40L	 (40	 ng/ml,	 Sigma-Aldrich).	 As	 indicated,	 3-NPA	 (1.5	μm/ml,	 Sigma-Aldrich)	 or	 ML-385	 (5	 μm/ml,	 Sigma-Aldrich)	 was	 added.	 Supernatants	 were	harvested	48	hours	after	activation,	and	concentrations	of	 IL-6	and	 IL-8	were	measured	using	Legendplex,	human	multiplex	Panel	(Biolegend),	according	to	the	manufacturer’s	instructions.		
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RNA	mediated	interference	B-LCLs	(2x106)	from	patients,	and	MZ-like	B-LCLs	from	healthy	controls,	were	transfected	with	pools	of	siRNA	targeting	FH,	SDHA,	or	control	scrambled	siRNA	(QIAGEN)	for	48	hours,	using	the	AMAXA	cell	line	V	nucleofection	kit	(Lonza,	Switzerland).	Knockdown	efficiency	was	assessed	by	immunoblot	analysis.		
Fumarate	quantification	To	 measure	 cellular	 fumarate	 abundance,	 ELISA	 microplate	 assay	 kits	 (Abcam)	 were	 used	according	 to	manufacturer’s	 instructions.	 In	 brief,	 5x105	MZ-like	B-LCLs	 from	healthy	 controls	were	homogenized	in	assay	buffer	and	centrifuged	at	13’000	x	g	 for	10	min.	Reaction	mix	was	added	 to	 each	 standard	 and	 test	 sample,	 followed	 by	 an	 incubation	 of	 1	 hour	 at	 37°C.	Absorbance	was	measured	at	450	nm	using	a	microplate	reader.	
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SUPPLEMENTAL	MATERIAL			
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Figure	S1:	(A)	Age	distribution	of	basal	respiration	(OCR)	and	basal	glycolysis	(ECAR)	in	primary	B	cells	from	HCs	(n	=	15)	and	PAD	patients		(n	=	14).	(B)	Basal	respiration	(OCR)	in	primary	B	cells	from	female	vs.	male	and	CMV–	vs.	CMV+	HCs	(n	=	12-15)	and	PAD	patients	(n	=	13-14).	(C)	Relative	distribution	of	CD4+	and	CD8+	T	cells	subsets	from	a	HC	and	a	PPBL	patient.	(D)	Representative	mitochondrial	perturbation	profiles	 (OCR	(left),	ECAR	(right))	of	primary	T	cells	 from	HCs	and	PPBL	patients.	Summary	graphs	present	basal	respiration	(OCR	–	left)	and	basal	glycolysis	(ECAR	–	right)	of	primary	T	cells	from	HCs	(n	=	14)	and	PPBL	patients	(n	=	3).	Pooled	data	are	presented	as	mean	±	SEM.	Statistical	significance	was	assessed	by	unpaired	t-test	(B,D).	*p	<	0.05,	**	p	<	0.01,	ns,	not	significant.		
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Figure S2
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Figure	S2:	(A)	Frequency	distributions	of	 the	residues	 from	the	N-terminal	SDHA	(left)	and	SDHB	(right)	 involved	 in	 inter-domain	hydrogen	bonds	in	simulations	with	SDHA	WT	and	SDHA	A45T.		
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Figure S3
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Figure	S3:	(A)	Heatmap-visualization;	 transcript	 abundance	of	 genes	 involved	 in	 glycolysis	 and	glutamine	metabolism,	 in	primary	MZ-like	B	cells	from	HCs	(n	=	4)	and	primary	B	cells	form	PPBL	patients	(n	=	3).	(B)	Heatmap-visualization;	transcript	abundance	of	genes	involved	in	respiratory	complex	I,	III,	IV	and	V	in	primary	MZ-like	B	cells	from	HCs	(n	=	4)	and	primary	B	cells	form	PPBL	patients	(n	=	3)					
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